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AbstractABSTRACT 
 
Regular exercise and physical activity are cornerstones in the prevention and treatment of 
numerous chronic conditions, such as type 2 diabetes, coronary heart disease, and age-
related sarcopenia. The associated health benefits arise from a number of tissues but due to 
its high plasticity skeletal muscle plays a pivotal role. The resident stem cells of skeletal 
muscle tissue, so called Satellite cells (SCs), contribute significantly to skeletal muscle 
adaptation and hence, maintenance of healthy tissue. The specific stimuli regulating SC 
development, i.e. activation, proliferation, an differentiation, depend on the form of exercise 
and consist of hormonal, mechanical, and metabolic signals. While hormonal and mechanical 
factors have been well documented, the importance of metabolic stimuli such as Lactate (La) 
remains less clear. La is produced continuously under aerobic conditions, but elevated levels 
occur during exercise when glycolysis is increased. La is able to induce muscle adaptation, 
but the underlying molecular mechanisms are not yet understood. Therefore, one aim of this 
study was to identify the phenotypical effects of high La levels as observed during resistance 
or high intensity endurance training on the proliferation and differentiation in a model of 
activated SCs, C2C12 cells. Furthermore, possible signalling targets for La, such as p38 
mitogen-activated protein kinase (p38 MAPK), and subsequent histone modifications were 
investigated. Lastly, to confirm the observed mechanisms in vivo, a human intervention study 
was conducted. Treatment with La (10 mM, 20 mM) increased the serum deprivation-induced 
withdrawal from the cell cycle and initiated early differentiation in C2C12 cells as analysis of 
gene expression and protein patterns of cell cycle (Ki67, Trp53, and Cdkn1a) and 
differentiation markers (Pax7, Myf5, myogenin, and myosin heavy chain) revealed. However, 
La delays late differentiation in a dose-dependent manner. La-induced production of ROS, 
marked by high 8-epi-PGF2α levels, might at least be partly responsible as the effects 
induced by La were reversible by the addition of the antioxidants ascorbic acid, N-
acetylcysteine, or linolenic acid. Observed downregulation of p38 MAPK activation and its 
downstream modifications histone 3 lysine 4 (H3K4) and histone 3 lysine 27 (H3K27) 
trimethylation suggests that La inhibits late differentiation progress by this mechanism which 
is crucial for muscle specific gene transcription. Experiments using the p38 specific inhibitor 
SB203580 add further evidence for this hypothesis. Additionally, it was demonstrated that 
diminished p38 MAPK activation and subsequent histone modifications are conserved in 
differentiated muscle tissue in vivo. Conclusively, the reported data confirm that La modifies 
skeletal muscle adaptation via a ROS-sensitive signalling network by delaying late 
differentiation of SCs, an important mechanism of skeletal muscle adaptation. This 
conclusion implies reassessment of traditional views on training design and periodisation in 
order to accelerate skeletal muscle adaptation. 
Zusammenfassung 
 
2 
 
ZusammenfassungZUSAMMENFASSUNG 
 
Regelmäßige körperliche Aktivität ist in der Prävention und Therapie vieler chronischer 
Krankheiten, wie zum Beispiel Typ 2 Diabetes, koronare Herzkrankheiten und altersbedingte 
Sarkopenie von großer Bedeutung. Die positive Wirkung von körperlicher Aktivität sind u. a. 
auf die Adaptation der Skelettmuskulatur zurückzuführen, welche eine hohe Plastizität, d.h. 
eine sehr hohe Anpassungsfähigkeit auf wiederkehrende Reize, besitzt. Die 
gewebsspezifischen Stammzellen der Skelettmuskulatur, sogenannte Satellitenzellen (SCs), 
tragen wesentlich zur Skelettmuskelanpassung und damit zur Gesunderhaltung des 
Gewebes bei. Die Satellitenzellentwicklung, d.h. die Aktivierung, Proliferation und 
Differenzierung von SCs, wird durch verschiedene Stimuli reguliert, welche von der Art des 
Trainings abhängen. Diese können hormonellen, mechanischen oder metabolischen 
Ursprungs sein. Während hormonelle und mechanische Effekte gut beschrieben sind, bleibt 
die Rolle der metabolischen Reize, wie zum Beispiel Laktat (La), unklar. La wird ständig 
produziert, vor allem aber bei körperlicher Aktivität und der damit verbundenen erhöhten 
Glycolyserate. Kürzlich wurde gezeigt, dass La die Genexpression beeinflussen und damit 
die Muskelanpassung fördern kann. Die zugrunde liegenden molekularen Mechanismen sind 
aber unbekannt. Daher waren die Ziele dieser Arbeit zum einen, die Aufklärung der 
phänotypischen Effekte erhöhter Laktatkonzentrationen, wie sie bei Kraft- oder 
hochintensivem Ausdauertraining auftreten, auf die Proliferation und Differenzierung in 
einem Modell aktivierter SCs (C2C12-Zellen). Desweiteren sollten Signalmoleküle, die 
potentiell durch La modifiziert werden könnten, wie z.B. p38 mitogen-activated protein kinase 
(p38 MAPK) und darauf folgende Histonmodifikationen untersucht werden. Außerdem sollte 
eine humane Trainingsstudie zeigen, ob die aus der Zellkultur gewonnenen Erkenntnisse 
auch in vivo zutreffen. Genexpressions- und Proteinanalysen von Zellzyklus- (Ki67, Trp53, 
Cdkn1a) und Differenzierungsmarkern (Pax7, Myf5, Myogenin, Myosinschwerekette) an 
C2C12-Zellen, die mit physiologisch relevanten La-Konzentrationen (10, 20 mM) inkubiert 
wurden, zeigten, dass La den durch den Serumentzug verursachten Zellzyklusaustritt 
verstärkt und die frühe Differenzierung einleitet. Die späte Differenzierung wird jedoch durch 
La zeitlich und dosisabhängig verzögert. Die Produktion von ROS scheint bei der Vermittlung 
des La-Effekts eine wichtige Rolle zu spielen. Dieses beruht auf der erhöhten 8-epi-PGF2α-
Bildung und der Umkehrbarkeit des Laktateffekts durch Zugabe der antioxidativen 
Substanzen Ascorbinsäure, N-Acetylcystein oder Linolensäure. Desweiteren konnte eine 
Reduktion der p38 MAPK-Aktivierung und der Trimethylierung des Histons 3 an den Lysinen 
4 und 27 (H3K4me3 und H3K27me3) durch La festgestellt werden. Auch Versuche unter 
Einsatz des p38-spezifischen Inhibitors SB203580 bestätigen, dass die 
Differenzierungsverzögerung durch eine Hemmung von p38 MAPK und der damit 
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zusammenhängenden, für die muskelspezifische Genexpression notwendige H3K4me3 und 
H3K27me3 zustande kommt. Zudem konnte die Konservierung dieses Mechanismus auch 
im humanen Modell in vivo gezeigt werden. Zusammenfassend hat La einen modifizierenden 
Effekt auf die Skelettmuskeladaptation. Dieser besteht in der Verzögerung der späten 
Differenzierung von SCs, welche ROS-vermittelt auftritt. Dieser Schluss impliziert ein 
Überdenken und Modifikation der bisherigen Trainingsperiodisierung, um die 
Skelettmuskelanpassung zu beschleunigen.  
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1 IntroductionINTRODUCTION 
1.1 Exercise and physical activity and associated health benefits 
Regular exercise and physical activity are cornerstones in the prevention, management, and 
treatment of numerous chronic conditions, such as hypertension, coronary heart disease, 
obesity, type 2 diabetes mellitus, and age-related sarcopenia (1, 2). Exercise and physical 
activity loweres the risk of all cause mortality, coronary heart disease, stroke, bone-related 
diseases, colon and breast cancer, and depression (3, 4). The associated health benefits 
arise from a number of tissues. However, skeletal muscle plays a pivotal role as detailed 
below. It makes up ~40% of body mass and accounts for ~30% of the basal metabolic rate 
(5). It is the predominant (~80%) disposal site of glucose under insulin-stimulated conditions 
(6) and a major regulator of glycemic control and metabolic homeostasis (7). One striking 
physiological characteristic of skeletal muscle tissue is its high plasticity, i.e. it has a high 
ability to adapt to sustained stimuli. Within the tissue, exercise and physical activity lead to 
activation of signalling pathways which induce acutely altered gene expression and/or protein 
synthesis. This is subsequently followed by chronic functional and structural adaptations. 
Additionally, muscular adaptations not only occur through changes within the existing muscle 
fibre but also by altering extracellular components. Extracellular matrix remodelling, 
capillarisation, and especially the addition of skeletal muscle stem cells, so called Satellite 
cells (SCs), to myofibres contribute further to functional adaptation and remodelling, and 
hence maintenance of healthy skeletal muscle tissue. 
To date it is difficult to recommend specific exercises and activities to achieve a specific 
outcome as the molecular mechanisms of muscular adaptation in response to different forms 
of exercise are at large poorly understood. Generally, three forms of exercise can be 
distinguished: endurance, resistance, and patterned movement exercise (8). While the latter 
deals with a motor program in the central nervous system resulting in only small biochemical 
changes within the muscle, the former two have a large impact on muscle phenotype (8). 
Resistance training which is usually short in duration and high in intensity increases muscle 
wet mass (9), fibre cross-sectional area (10), RNA and protein content (11), and force 
generation capacity (12, 13), i.e. hypertrophy. This kind of training elicits health benefits for 
pathological conditions where muscle weakness comprises function such as sarcopenia and 
neuromuscular disorders, or following immobilisation, prolonged bed rest or injury (14). In 
contrast, endurance training which is comprised of low to moderate intensities and high 
volume induces adaptational changes that differ immensely. Here the main effects observed 
within skeletal muscle tissue are increased capillarisation (15) and mitochondrial mass (16), 
decreased glycolytic (17) and increased oxidative enzymes (18), increased slow contractile 
and regulatory proteins (17, 19), and a decrease in fast fibre area (19). Hence, this kind of 
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training is recommended in the prevention and treatment of cardiovascular diseases and 
metabolic abnormalities which involve coronary heart disease or obesity risk factors, such as 
elevated blood lipids. 
The question arising with these findings of distinct adaptations is how skeletal muscle is able 
to respond differentially to what appears to be the same set of signals. Both forms of 
exercise elicit changes in intracellular calcium, deplete nutrients, and lead to energy stress 
(20). Nevertheless, the duration and intensity of those signals vary and might deliver the 
explanation for exercise form-specific adaptations. A lot of research in this field investigated 
the distinct signalling pathways activated by each form of exercise. The main conclusions are 
that [1] resistance training induces adaptation mainly by increasing protein synthesis via the 
protein kinase B (PKB) and mammalian target of rapamycin (mTOR) pathways; and [2] that 
in response to endurance training adenosine monophosphate (AMP)-activated protein kinase 
(AMPK) and calcium and calmodulin-activated protein kinase (CaMKII) are thought to be the 
key signals inducing gene expression and hence, adaptation (20). AMPK has moreover been 
shown to activate TSC2, which deactivates mTOR and hence mTOR-initiated protein 
synthesis (21). This could explain the observation that endurance training impairs 
hypertrophic effects induced by concurrent resistance training (22). In contrast, strength 
training improves endurance performance, possibly by improved neuromuscular 
characteristics and running economy (23). However, underlying molecular mechanisms 
remain unknown. Regarding health benefits, it is now agreed upon that a combination of both 
forms of training elicits a favourable additive effect (24), reflected by recent exercise 
guidelines for health (2). This notion is further supported by the success of training that 
combines aspects of both classical forms of training, such as high intensity endurance 
training which uses modes of non-weight bearing endurance exercise (e.g. cycling) 
combined with high intensities and low volumes usually related to resistance training. This 
form of training is less time consuming but research shows that is as efficient as traditional 
endurance-based training regarding physiological adaptations (25). As little as 15 min all out 
cycle exercise spread out over 2 weeks are sufficient to increase muscular oxidative capacity 
reflected by protein content and/or maximal activity of mitochondrial enzymes (26, 27). 
Several weeks of low-volume, high intensity cycling are furthermore associated with 
increased resting glycogen content (26), increased capacity of whole-body and skeletal 
muscle lipid oxidation (28), and enhanced peripheral vascular structure and function (29). 
The underlying molecular mechanisms are only partly understood. However, HIT activates 
peroxisome proliferator activated-receptor γ coactivator-1α (PGC1α) which is considered the 
master regulator of mitochondrial biogenesis in skeletal muscle (30). As evidence suggests 
that the intensity of exercise is the key factor regulating PGC1α activation in human muscle 
(31) this result is not surprising. Further investigations identified AMPK and p38 mitogen-
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activated protein kinase (p38 MAPK) as upstream activators of PGC1α following high 
intensity endurance training (32), possibly via increased ROS generation (33). Although the 
beneficial effects of this kind of training have been established, metabolic signals initiating 
adaptational processes remain to be identified. 
1.2 Satellite Cells and skeletal muscle adaptation 
Next to altered gene expression and/or protein synthesis in skeletal muscle fibres, another 
important aspect of skeletal muscle adaptation or regeneration is the activation, proliferation, 
and differentiation of SCs, i.e. myogenesis. SCs lie quiescent between the basal membrane 
and the sarcolemma and were first discovered by Alexander Mauro who named them SCs 
for their localisation surrounding a muscle fibre (34). They originate from the somites and 
make up the necessary muscle specific stem cell pool needed for embryonic and adult 
myogenesis. In postnatal myogenesis, as it occurs in response to training or muscle injury, 
SCs are activated by multiple stimuli to become myoblasts. Myoblasts proliferate and 
increase in number, but at some point exit the cell cycle to enable differentiation and 
eventually fuse with existing myofibres to enlarge, to replace or to repair muscle tissue 
(Figure 1.1). 
The role of SCs in muscle regeneration has been well characterised. However, their function 
in mediating exercise-induced adaptations is lively debated (35). Most emphasis has been 
placed upon elucidating the contribution of SCs in skeletal muscle adaptation in response to 
resistance training, where muscle fibre hypertrophy is the main adaptation. It is discussed 
whether SCs are necessary for hypertrophic events (36). However, the current literature 
suggests that after an initial phase where muscle hypertrophy mainly occurs through 
increased protein synthesis by myonuclei within the muscle fibre, the addition of new 
myonuclei to existing myofibres is required (14) for the maintenance of myonuclear domains, 
i.e. a theoretical cytoplasmic area associated with a myonucleus, to allow for sufficient supply 
of genetic machinery and protein synthesis without changing the kinetics of protein 
production for each nucleus (7). Only a few studies have looked at the role of SCs in 
response to training regimens that do not induce hypertrophy, e.g. high intensity endurance 
training as mentioned above. Results from an animal study (37) and two human studies (38, 
39) have implied that endurance-based training enhances the SC pool. Furthermore, the 
literature suggests that this enhancement is influenced by rather the intensity than the 
duration of exercise (40). This would also explain the results of Snijders et al. who did not 
find a change the satellite cell content in diabetes type 2 patients following 6 month of a 
continuous, endurance-type exercise programme (41). Their workload corresponded to about 
75% VO2max, whereas the other studies used intermittent protocols with intensities around 75-  
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Figure 1.1: Satellite cell development and markers of myogenesis. A + B Fluorescent microscopic image of a SC 
on a mouse muscle fibre (yellow fluorescent protein – SC; blue – DNA). Modified from (52). C SC myogenesis 
scheme and markers typical for each stage. SCs lie quiescent underneath the basal membrane but can be 
activated by training. Activated SCs are called myoblasts that proliferate and increase in number. At some point 
they exit the cell cycle and start differentiating and fusing to form myotubes. Pax7 is expressed in quiescent, 
proliferating and early differentiating cells. Myf5 and MyoD expression increases during the proliferative and early 
differentiation phase, whereas myogenin marks the commitment to differentiation. During late differentiation, i.e. 
that of sarcomeric assembly, MHC expression is initiated. SC – Satellite cell; Pax7 – paired box transcription 
factor 7; Myf5 – myogenic factor 5; MyoD – myogenic determination protein; MHC – myosin heavy chain. Modified 
from (167). 
 
95% VO2peak (38) or 75-95% HRmax (39) i.e. intensities that were considerably higher. 
Moreover, one study provides evidence that SCs are not only activated by high intensity 
endurance training and lead to increase SC availability but also have a role in functional 
adaptations following non-hypertrophic training such as skeletal muscle fibre remodelling 
(42). Taken together, the current literature suggests that in response to resistance and high 
intensity endurance training SCs are activated and play a crucial role in hypertrophic and 
even possibly non-hypertrophic skeletal muscle adaptations. 
1.3 Myogenesis and its regulatory epigenetic modifications 
During myogenesis, SCs and myoblasts underlie a strict sequential expression pattern of 
different transcription factors and structural muscle proteins (43). These can be used as 
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markers to study the proliferation and differentiation behaviour of this cell population in vitro. 
One of these proteins is the paired-box transcription factor 7 (Pax7). It is expressed during 
quiescence, activation, and proliferation as well as early differentiation and it is the most 
commonly used marker to identify SCs as such (44–46). To briefly describe the expression 
pattern during differentiation which is extensively reviewed in (47), a reduction of Pax7 
expression coincides with the withdrawal from the cell cycle and transition from the 
proliferative to the differentiation phase. This state is also accompanied with the onset of the 
expression of several myogenic regulatory factors (MRFs). This group of muscle specific 
transcription factors of the basic helix-loop-helix (bLHL) class of DNA binding proteins 
consists of four members: myogenic factor 5 (Myf5), myogenic determination protein (MyoD), 
muscle-specific regulatory factor 4 (MRF4), and myogenin. Whereas MyoD and Myf5 are 
soon expressed following activation and early differentiation of SCs, myogenin is not 
expressed until a later stage marking the commitment to differentiation to which it is essential 
in adult myogenesis (48, 49). The exact expression pattern of MRF4 is less clear. It is 
expressed before as well as after myogenin expression (50, 51). At an even later stage of 
differentiation, i.e. that of sarcomeric assembly, the expression and synthesis of myosin 
heavy chain (MHC) indicates end-terminal differentiation of myotubes and myofibres. A 
number of stimuli that activate SCs were identified and are comprehensively reviewed in (52) 
and (53). Among these are transforming growth factor β, myostatin, insulin-like growth factor 
1, fibroblast growth factor, hepatocyte growth factor, and the wingless-type MMTV integration 
site (Wnt) family of proteins. Although a number of SC activators were identified, their 
mechanisms have not been completely understood. Furthermore, some factors possibly 
might have not even been identified as yet. 
The gene expression pattern during myogenesis is regulated by epigenetic modifications (54, 
55), especially histone modifications. Generally, 147 bp of double stranded DNA are 
wrapped around a histone octamer consisting of two copies of each core histone, namely 2A, 
2B, 3, and 4, forming so called nucleosomes which make up the basic units of chromatin. 
This ensures compactness of the genome to fit into the nuclei but also results in limited 
accessibility for the transcription machinery and hence hindered gene expression. This 
structure can however be reversibly modified to allow gene expression if indicated. Histone 
modifications include acetylation, methylation, phosphorylation, and ubiquitination and 
regulate gene expression differently. Especially histones 3 and 4 (H3 and H4) are prone to 
such alterations (56). Histone acetylations, the most common post-translational histone 
modification, lead to enhanced transcriptional activity. Histone acetyltransferases (HAT) and 
histone deacetylases (HDAC) add or remove, respectively, acetyl groups from histone lysine 
residues, converting the charge of the residue and alter DNA-histone binding as well as 
nucleosome associations (57, 58). Histone methylation however, is more complex as it can 
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either increase or repress gene expression. It occurs most commonly at lysine and arginine 
residues where up to three or two methyl groups can be added, respectively (59, 60). 
Methylated residues provide binding sites for chromodomains (61) and PHD domains (62–
64) which are both related to chromatin remodeling. Trimethylation of H3 at lysine 4 
(H3K4me3) occurs in as many as 75% of all gene promoters in some cells (65, 66) and it is 
positively correlated with active gene transcription (67, 68) marking its critical role in gene 
expression. In contrast, trimethylation of H3 at lysine 9 and 27 (H3K9me3 and H3K27me3) 
as well as H4 at lysine 20 (H4K20me3) are linked to gene repression. Adding to the 
complexity compared to histone acetylation is the finding that methylation of different 
residues appears to be catalysed by different lysine methyltransferases (KMT). They are two 
forms of KMT: polycomb group (PcG) and trithorax group (TrxG) proteins that work 
antagonistically. For example, H3K4 methylation is mediated by KMT2, a TrxG member that 
acts as the subunit of the histone methyltransferase complex absent, small, or homeotic-like, 
variant 2 (Ash2L), whereas H3K27 is methylated by PcG proteins from the KMT6 family, 
namely enhancer of zeste homolog 1 and 2 (Ezh1 and Ezh2) that act as the active subunit of 
the polycomb repressor complex 2 (PRC2), another histone methyltransferase complex (69). 
The H3K27me3 mark is dominant to H3K4me3 (67). So, in order for gene transcription to 
occur at gene loci marked with both modifications, H3K27me3 has to be demethylated. This 
is achieved by the lysine demethylase family 6 (KDM6) members ubiquitously transcribed 
tetratricopeptide repeat, X chromosome (UTX) and Jumonji domain-containing protein 3 
(JMJD3) (70, 71, 71).  
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Figure 1.2: Histone modifications H3K4me3 and H3K27me3 during SC proliferation and differentiation. A During 
proliferation and cell cycle progression Pax7 and Myf5 genes are expressed. These genes are known to be 
marked with H3K4me3. Myf5 is important for the progress from the proliferative to the differentiation stage. The 
H3K4me mark is established through the recruitment of TrxG proteins by Pax7. B In terminally differentiating SCs 
Pax7 and cell cycle progression genes are silenced. This repression involves PcG mediated H3K27me3 at the 
promoter regions of the respective genes. At this time point MyoD collaborates with Mef2d and Six4 to establish 
the H3K4me3 mark at the myogenin promoter, initiating its expression. H3Kxme3 – trimethylated histone 3 at 
lysine x; SC – Satellite cell; Pax7 – paired box transcription factor 7; Myf5 – myogenic factor 5; TrxG – trithorax 
group protein; PcG – polycomb group protein; MyoD – myogenic determination protein; Mef2d – myocyte 
enhancer factor 2d; Six4 – Six homeobox 4. Modified from (69). 
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During myogenesis (Figure 1.2), Pax7 expression is switched off in order for differentiation to 
proceed. p38 MAPK promotes recruitment of PRC2 to the Pax7 promoter via interaction with 
Ezh2, which is the direct substrate for phosphorylation-mediated association with Ying Yang 
1 (YY1). This leads to the enrichment in chromatin occupancy by Ezh2/YY1 which mediates 
Pax7 repression (72, 73). During proliferation cell cycle genes are enriched with the 
permissive H3K4me3 mark (74). However, when differentiation is initiated, the repressive 
H3K27me3 conformation accumulates (75) by a mechanism involving E2F family members 
and the retinoblastoma protein (pRb) (76). Furthermore, during the proliferative state, Myf5 
expression is induced via a Pax7-dependent recruitment of a KMT2 family member and 
subsequent H3K4me3 (77). Myogenin expression marks the commitment to differentiation in 
myoblasts. Here, the repressive H3K27me3 is removed during differentiation (78, 79). 
Furthermore, Rampalli et al. showed that Ash2L is recruited by Mef2d and targets the 
H3K4me3 mark to specific promoters, such as myogenin (80). The same group further 
demonstrated that this recruitment is regulated through the p38 MAPK phosphorylation of 
Mef2d, linking the p38 MAPK signalling pathway with the activation of muscle-specific genes 
in myogenesis (79, 80). The histone modification H3K9me3 is controversially discussed in 
the literature. Although it has been thought to repress gene expression (81, 82), it was 
recently shown to also be able to induce the same (83). The H4K20me3 is another histone 
methylation known to play a role in myogenesis, but so far it was only shown to affect 
myogenesis by the repression of myogenin with the further interpretation being elusive (84). 
Taken collectively, the current literature suggests that epigenetic events, in particular histone 
trimethylation of H3K4 and H3K27, are fundamental to the regulation of myogenesis. 
However, apart from histone methylations, other epigenetic modifications might be important 
during myogenesis. 
1.4 The role of p38 MAPK in skeletal muscle adaptation 
Interestingly, a number of the above mentioned events are regulated via the p38 MAPK. 
MAPKs are a family of protein kinases, i.e. proteins that covalently bind a phosphate to a 
threonine (Thr), serine (Ser), or tyrosine (Tyr) side chain of other proteins and thereby alter 
their targets activity or interactions with other molecules. This leads to changes in cell cycle 
machinery, gene expression, protein synthesis, differentiation, metabolism, migration, and 
cell death (85, 86). 3 subfamilies have been well characterised in the literature: extracellular 
signal-regulated kinases (ERK1/2), the c-Jun NH2 terminal kinases (JNK1/2/3), and p38 
MAPK (p38α, p38β, p38γ, p38δ). During myogenesis, p38 MAPK has been identified as a 
major regulator (87, 88). Upon differentiation cues, p38 MAPK is phosphorylated by the 
upstream MAPK kinases 3 and 6 (MKK3 and MKK6) at threonine 180 and tyrosine 182 (p-
p38), and activated. The isoforms p38α and p38β were shown to be involved during 
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myoblasts differentiation (89–91). The role of p38γ in myogenesis is so far not fully 
understood. Although it is expressed in skeletal muscle and its expression is upregulated 
during myogenesis (90, 92–94), a differentiation regulatory effect could not be confirmed. 
p38δ appears to play no important role in skeletal muscle (reviewed in (95)). 
Additionally to the histone methylations described above, p38 MAPK has additional pro-
myogenic effects (Figure 1.3). Upon differentiation signals, activated p38 MAPK directs 
switch/sucrose non-fermentable (SWI/SNF) and Ash2L-KMT containing complexes to 
regulatory muscle genes, promoting their transcription (96–98). Furthermore, p38 is directed 
to the chromatin of muscle specific genes through interactions with E47 (99), Mef2d (80) and 
BAF60 (96). CAM-downregulated by oncogenes (CDO) is a transmembrane protein of the Ig-
fibronectin III repeat subfamily. It can also activate p38 MAPK which in turn leads to the 
formation of MyoD-E47 heterodimers that bind to E-box sequences on the regulatory regions 
of muscle-specific genes (100, 101). It is moreover involved in cell cycle exit. p38 MAPK 
decreases cyclin D1 expression and pRb phosphorylation, therefore promoting cell cycle 
withdrawal and differentiation progression (102). 
 
 
 
 
Figure 1.3: A model for the activity of p38 MAPK in myogenesis. p38 MAPK is activated by MKK3/6 in muscle 
cells and subsequently phosphorylates various substrates contributing to myogenesis. It induces the 
transcriptional activity of Mef2 transcription factors and promotes the heterodimerisation of E47 with MyoD. 
Additionally, it induces Myf5 expression. p38 MAPK recruits the SWI/SNF complexes to muscle promoter regions, 
thereby affecting the epigenetic landscape. p38 MAPK – p38 mitogen-activated protein kinase; MKK3/6 – MAPK 
kinase 3/6; Mef2 – myocyte enhancer factor 2; MyoD – myogenic determination protein; Myf5 – myogenic factor 
5; SWI/SNF - switch/sucrose non-fermentable. Modified from (87). 
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In addition to its regulatory role during the differentiation of SCs, p38 MAPK has also been 
shown to possess the ability to induce skeletal muscle adaptation within differentiated muscle 
tissue in response to exercise or physical activity. The level of phosphorylation and hence 
activation depends on the exercise status, i.e. p38 MAPK is more phosphorylated in 
untrained subjects compared to highly trained athletes (103, 104). This in turn leads to the 
stimulation of activating transcription factor 2 (ATF2) and Mef2 (105) which are upstream 
transcription factors of the PGC1α gene and induce its expression following exercise (31, 
105, 106). These data implies a superior role of p38 MAPK during SC differentiation and 
regulating gene expression in response to exercise and physical activity making it a key 
molecule for skeletal muscle adaptation. 
1.5 Exercise and physical activity and histone modifications 
Epigenetic events are not only important during myogenesis, but also regulate skeletal 
muscle fibre adaptations in response to exercise and physical activity through exercise-
induced alterations of the metabolic state (107–109). This implies that epigenetic responses 
should also elicit an intensity-dependent effect. This concept was supported by the finding of 
decreased whole genome methylation in muscle biopsies from sedentary subjects after an 
acute bout of exercise. Exercise induced dose-dependent expression of PGC1α and Mef2a 
mRNA accompanied by a pronounced hypomethylation on both promoters, a state 
associated with gene induction (110). Proposed metabolic stimuli to regulate epigenetic 
events following exercise are AMPK and CaMKII. Both have a pronounced regulatory effect 
on class II HDACs. This class consists of HDAC 4, 5, 7, and 9 and are enriched in striated 
muscle (111). They exert their function by association with the Mef2 family of transcription 
factors to repress Mef2-dependent transcription (112). Following a single bout of exercise, 
HDAC5 was found to be less abundant within the nucleus and less HDAC5 was associated 
with Mef2 (113). These changes were accompanied by increased Mef2-binding activity to the 
DNA (114) and elevated glucose transporter 4 (GLUT4) mRNA levels (113). The concept 
that HDAC5 nuclear abundance is reduced following exercise could also be confirmed for 
HDAC4 (115). AMPK and CaMKII can both phosphorylate HDAC4 and 5, mediate their 
nuclear export and hence render these enzymes to suppress histone acetylation (115, 116). 
Although this direct relationship was shown for GLUT4, other oxidative genes are also 
thought to be regulated by this mechanism (31, 117). The literature also suggests that 
epigenetic modifications are involved in the differential expression of the MHC genes and 
therefore determination of muscle phenotype (118). Changes in acetylation and methylation 
of H3 led to differential expression of MHC1, MHC2x, and MHC2b fibres in response to 
muscle unloading in skeletal muscle tissue of mice (119, 120). A knockout model of HDAC5 
in mice furthermore suggested a regulatory role for slow fibre formation. Following HDAC5 
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loss, MHC1 fibre type increased (121). Collectively, epigenetic modifications in response to 
exercise provide evidence for the role of metabolic control of gene expression and the 
concept that skeletal muscle adaptation via epigenetic mechanisms is therefore exercise-
intensity dependent. However, knowledge of epigenetic alterations, especially histone 
modifications is scarce. Understanding the exercise and physical activity-dependent 
alterations in skeletal muscle gene expression by altering the epigenetic landscape will add 
new implications to exercise and physical activity prescriptions in prevention and therapy.  
1.6 Lactate as a metabolic signal of gene expression 
Muscle phenotype alterations only occur after repeated bouts of exercise. Over time, skeletal 
muscle demonstrates remarkable plasticity in response to contractile activity by functional 
remodelling (122, 123). Repeated stimuli triggered in each single session at a sufficient 
frequency are necessary to induce a new steady state within the muscle (8) including the 
activation and regulation of the development of SCs necessary for adaptation. These signals 
include hormonal factors (124), mechanical stimuli (125), and alterations of the metabolic 
state (126). While the importance of hormonal and mechanical factors has been well 
established (127, 128), the importance of metabolic influences especially in resistance and 
high intensity endurance training is indicated (129) but remains elusive. 
The metabolic responses to resistance and high intensity endurance exercise are thought to 
be initiators of skeletal muscle adaptation by influencing motor unit activation, hormones, and 
muscle damage (130). The challenge arising with this idea is to identify the intracellular 
signalling molecules that occur at different concentrations depending on the exercise 
intensity. One possible candidate is La. All muscle contractions require energy in form of 
adenosine triphosphate (ATP). ATP stores are limited within the muscle fibre and therefore 
ATP has to be resynthesised at its rate of use during muscular activity in order to maintain 
contractions. During high intensity exercise the main source of ATP is glycolysis that 
produces pyruvate. Pyruvate is transferred into mitochondria for further oxidative 
phosphorylation and ATP resynthesis. However, if exercise intensity and the ATP breakdown 
rate exceed the rate of oxidative phosphorylation, pyruvate accumulates in the cytosol and is 
converted to lactic acid by the lactate dehydrogenase enzyme. Lactic acid is almost fully 
dissociated to La and protons at physiological pH, resulting in La accumulation within the 
working muscle. La has long been considered a metabolic waste product and its 
accumulation was thought to be the cause of the decrease in muscle pH and hence, muscle 
fatigue. This idea has changed massively in the past. La is now recognised as a metabolic 
stimulus able to induce skeletal muscle adaptation. For example, La has been shown to 
increase norepinephrine and growth hormone levels following resistance exercise (131–133). 
Furthermore, it increases recruitment of motor units at a given load (131, 134). La was also 
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shown to correlate with muscle damage (135). These events lead to enhanced skeletal 
muscle adaptation and therefore underline the role of La as a metabolic stimulus for altering 
muscle phenotype. 
The aforementioned La effects are indirect and have no immediate impact on muscle gene 
expression or protein synthesis. However, recently Hashimoto et al. demonstrated that La 
increases monocarboxylate transporter-1 (MCT-1) and PGC1α mRNA content indicating the 
induction of mitochondrial biogenesis in L6 rat myoblasts (136). La was termed “Lactormone” 
as it possesses signalling properties inducing gene expression necessary for skeletal muscle 
adaptation (137). 
With the identification of La as a gene expression-altering molecule in skeletal muscle, the 
question arises which signalling pathways are involved in the mediation. It was previously 
shown that in macrophages La concentrations correlated with the induction of angiogenic 
factor gene expression (138). Later on this effect was shown to be mediated by H2O2 (139). 
H2O2 is a member of the reactive oxygen species (ROS) which also include the superoxide 
anion (·O2-) and hydroxyl radicals (·OH). Although H2O2 is not a free radical and a weaker 
oxidising agent, it can be oxidised into the extremely active and toxic ·OH (140) and with 
other ROS can affect signalling cascades that affect cell growth, proliferation, migration, and 
apoptosis (141). ROS are produced at various sites in skeletal muscle. Main sources are 
Complex I and III of the electron transport chain of mitochondria (142). Furthermore, NADPH 
oxidases (143) and xanthine oxidase (144) contribute to ROS formation within the cytosol of 
skeletal muscle. ROS-induced redox signalling regulates numerous transcription factors and 
alter gene expression and hence skeletal muscle phenotype (145). One known target of ROS 
are MAPKs (146). Applying the above mentioned mechanism suggested in macrophages to 
muscle tissue, investigations confirmed that La increases intracellular H2O2 and therefore 
ROS, and subsequently promoted binding of ROS-sensitive transcription factors to DNA 
(136). In the same study it was furthermore speculated that ROS led to the downstream 
activation of MAPK (136). However, no data on La and its effect on the MAPKs are available 
for skeletal muscle and hence the role of these key regulators in La-signal mediation remains 
to be investigated. Taken together, La is an important signalling molecule for skeletal muscle 
adaptations. Although a La-activated ROS-sensitive signalling network has been suggested, 
conclusive data is missing if the La-effects depend on ROS-formation. Furthermore, 
molecular insights in the mediation of the La effect are not yet provided. 
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1.7 Aims 
 
1. To identify phenotypical effects of a simulated training microcycle of resistance or high 
intensity endurance training by intermittent incubation with a potent metabolic signalling 
molecule, i.e. La, on the proliferation and differentiation in a model for skeletal muscle 
stem cells. 
 
2. To investigate the role of ROS formation and oxidative stress induced by La and whether 
these could be responsible for the observed effects. 
 
3. To elucidate whether elevated La levels influence key signalling molecules of skeletal 
muscle adaptation, i.e. p38 MAPK, and its downstream epigenetic targets H3K4me3 and 
H3K27me3 to further establish the important role of La as a metabolic signal of gene 
expression. 
 
4. To confirm that these mechanisms in muscle stem cells are conserved during 
differentiation and remain active in differentiated muscle tissue exposed to similar La 
concentrations evoked by exercise in vivo. 
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2 Materials & MethodsMATERIALS & METHODS 
2.1 Materials 
2.1.1 Lab equipment and disposables 
Name Company 
A-Plan 10x/0,25 Ph1 objective Carl Zeiss AG, Jena Germany 
A-Plan 20x/0,4 Korr Ph2 objective (200M) Carl Zeiss AG, Jena Germany 
ApoChromat 63x/1,4 Oil DIC objective Carl Zeiss AG, Jena Germany 
ApoTome Carl Zeiss AG, Jena Germany 
Axiovert 200M microscope Carl Zeiss AG, Jena Germany 
AxioCam MRm Carl Zeiss AG, Jena, Germany 
Biofuge 13 Heraeus, Hanau, Germany 
BioMax Exposure Cassette Eastman Kodak Co, Rochester, NY, USA 
BIOSEN S-Line Lactate analyser EKF-Diagnostic GmbH, Barleben, Germany 
Bürker hemocytometer Karl Hecht, Sondheim, Germany 
CCD camera MC-3255 Sony, Tokio, Japan 
Cell Culture Flasks and Consumables BD Biosciences, San Jose, CA, USA 
CO2 Incubator C150 Binder, Tuttlingen, Germany 
CriterionTM electrophoresis chamber Bio-Rad Laboratories, Hercules, CA, USA 
CriterionTM XT 4-12% Bis-Tris gels Bio-Rad Laboratories, Hercules, CA, USA 
Filter Set 10 (exc. 450-490 nm; em. 515-565 nm) Carl Zeiss AG, Jena Germany 
Filter Set 14 (exc. 510-560 nm; em. 590 nm) Carl Zeiss AG, Jena Germany 
Filter Set 49 (exc. 365 nm; em. 545-450 nm) Carl Zeiss AG, Jena Germany 
Flexcylcer2 thermocycler AnalytikJena AG, Jena, Germany 
Glass cover slips VWR International, Langenfeld, Germany 
Hypodermic Needle Henry Schein, Melville, NY, USA 
ISOMED 2000 isokinetic equipment D & R Ferstl GmbH, Hemau, Germany 
Kinetic Microplate Reader MWG Biotech, Ebersberg, Germany 
KS300 microscope Carl Zeiss AG, Jena Germany 
Lamina Air Flow HS12 Heraeus, Hanau, Germany 
Leica CM1900 Cryostat  Leica Microsystems, Wetzlar, Germany 
Leitz Orthoplan Leica Microsystems, Wetzlar, Germany 
Lode Excalibur cycle ergometer Lode, Groningen, Netherlands 
Micro-dismembrator Braun, Melsungen, Germany 
Microscope slides VWR International, Langenfeld, Germany 
NalgeneTM Cryo 1°C Freezing Container Thermo Fisher Scientific, Waltham, USA 
pH-mV-meter Mettler Toledo, Gießen, Germany 
Plan Neofluar 20x/0.5 objective (KS300) Carl Zeiss AG, Jena Germany 
Poly-L-lysine microscope slides VWR International, Langenfeld, Germany 
PowerPacTM Basic power supply Bio-Rad Laboratories, Hercules, CA, USA 
PVDF membrane Pall Corporation, Port Washington, NY, USA 
Scaltec SBA53 weighing scale Scaltec Instruments, Heiligenstadt, Germany
Table centrifuge 5417R Eppendorf, Hamburg, Germany 
Thermocycler Mx3005P Agilent Technologies, Santa Clara, CA, USA 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
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Titramax 101 shaker Heidolph Instruments, Schwabach, Germany
TransBlot Turbo Bio-Rad Laboratories, Hercules, CA, USA 
Vortex Genie2 Scientific Industries, Bohemia, NY, USA 
X-OMAT x-ray films Eastman Kodak Co, Rochester, NY, USA 
2.1.2 Chemical and solutions 
Name Company 
100 bp DNA ladder Invitrogen, Karlsruhe, Germany 
Acetic Acid Merck, Darmstadt, Germany 
Agarose Biozym Scientific, Hessisch Oldendorf, Germany 
Aqua-Poly/Mount Polysciences, Warrington, PA, USA 
Ammonium chloride Merck, Darmstadt, Germany 
β-mercaptoethanol Invitrogen, Karlsruhe, Germany 
Bovine Serum Albumine PAA, Pasching, Austria 
BCP Molecular Research Center, Cincinnati, OH, USA 
bromphenol blue Merck, Darmstadt, Germany 
Cell lysis buffer (# 9803) Cell Signaling Technology, Danvers, MA, USA  
Complete Mini® Protease Inhibitor Cocktail Roche, Mannheim, Germany 
D-Glucose Roth Chemicals, Karlsruge, Germany 
DAB Sigma-Aldrich, Steinheim, Germany 
DAPI Invitrogen, Karlsruhe, Germany 
DMSO Merck, Darmstadt, Germany 
DMEM Invitrogen, Karlsruhe, Germany 
DPBS Invitrogen, Karlsruhe, Germany 
Dry milk powder Bio-Rad Laboratories, Hercules, CA, USA 
EDTA Sigma-Aldrich, Steinheim, Germany 
Ethanol Merck, Darmstadt, Germany 
Entellan® Merck, Darmstadt, Germany 
FBS PAA, Pasching, Austria 
Fresubin® protein energy drink Fresenius Kabi, Bad Homburg, Germany 
Gelatine Sigma-Aldrich, Steinheim, Germany 
Glucoseoxidase Sigma-Aldrich, Steinheim, Germany 
Glutamine Invitrogen, Karlsruhe, Germany 
Glycerol Merck, Darmstadt, Germany 
Glycine Merck, Darmstadt, Germany 
H2O2 Merck, Darmstadt, Germany 
HALT Phosphatase Inhibitor Cocktail Pierce Biotechnology, Rockford, IL, USA 
HD Green IntasScience Imaging Instruments, Göttingen, Germany 
Hemolyzing solution (ready-to-use) EKF Diagnostic GmbH, Barleben, Germany 
Horse Radish Peroxidase Dako, Glostrup, Denmark 
Isopropanol Merck, Darmstadt, Germany 
KH2PO4 Merck, Darmstadt, Germany 
L-Ascorbic Acid Sigma-Aldrich, Steinheim, Germany 
Linolenic Acid Sigma-Aldrich, Steinheim, Germany 
Methanol Merck, Darmstadt, Germany 
N-Acetyl-L-cysteine Sigma-Aldrich, Steinheim, Germany 
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Na2HPO4 Merck, Darmstadt, Germany 
NiSO4 Merck, Darmstadt, Germany 
Paraformaldehyde Roth Chemicals, Karlsruge, Germany 
Penicillin/Streptomycin Invitrogen, Karlsruhe, Germany 
Precision Plus Protein Standard Dual 
Color Bio-Rad Laboratories, Hercules, CA, USA 
RecoveryTM Cell Culture Freezing Medium Invitrogen, Karlsruhe, Germany 
RestoreTM Western Blot Stripping Buffer Thermo Fisher Scientific, Waltham, MA, USA 
SB203580 Cell Signaling Technology, Danvers, MA, USA  
Sodium bicarboante Invitrogen, Karlsruhe, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium dodecyl sulfate Amresco, Karlsfeld, Germany 
Sodium-L-Lactate Sigma-Aldrich, Steinheim, Germany 
Sodium pyruvate Invitrogen, Karlsruhe, Germany 
SuperSignal West Dura Luminol/Enhancer Thermo Fisher Scientific, Waltham, MA, USA 
TissueTek® O.C.T.TM Compound Sakura Finetek, Zoeterwoude, Netherlands 
Tris Merck, Darmstadt, Germany 
TritonX-100 Sigma-Aldrich, Steinheim, Germany 
TriReagent® Molecular Research Center, Cincinnati, OH, USA 
Trypsin-EDTA Invitrogen, Karlsruhe, Germany 
Tween20 Sigma-Aldrich, Steinheim, Germany 
XT MOPS running buffer Bio-Rad Laboratories, Hercules, CA, USA 
Xylol Alfred Quadflieg, Gelsenkrichen, Germany 
All compounds/used chemicals were adjusted for purity. 
2.1.3 Buffers and cell culture media 
0.1% gelatine 0.1% gelatine in DPBS 
PM 20% FCS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate in DMEM
(0 mM La) DM 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate in DMEM
5 mM La DM 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
5 mM sodium lactate in DMEM
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10 mM La DM 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
10 mM sodium lactate in DMEM
20 mM La DM 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
20 mM sodium lactate in DMEM
DM + DMSO 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
0.1% DMSO in DMEM
DM + SB 203580 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
0.1% DMSO 
10 µM SB203580 in DMEM
20 mM La DM + AA 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
20 mM sodium lactate 
100 µm ascorbic acid in DMEM
20 mM La DM + NAc 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
20 mM sodium lactate 
5 mM N-acetylcysteine in DMEM
20 mM La DM + LA 4% HS 
1% pen/strep 
4 mM glutamine 
0.15% sodium bicarboante
1 mM sodium pyruvate 
20 mM sodium lactate 
5 µM linolenic acid in DMEM
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TAE 40 mM Tris 
20 mM acetic acid 
1 mM EDTA pH = 8.0 
PBS  137 mM NaCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 pH = 7.4 
TBS  50 mM Tris 
150 mM NaCl pH = 7.6 
4% PFA 4% PFA in PBS pH = 7.4 
Permeabilisation 
solution 500 mM NH4Cl 
0.25% Tx-100 in PBS 
DAPI solution 300 nM DAPI in PBS 
PB 80 mM Na2HPO4·2 H2O 
20 mM NaH2PO4·H2O pH = 7.4 
DAB 2 mM DAB 
7.5 mM NH4Cl 
1.5 mM NiSO4 
10 mM D-glucose 
0.0004% glucose oxidase in PB 
Lysis buffer 1% Tx100 in TBS pH = 8.0 
Laemmli buffer 2x 125 mM Tris 
4% SDS 
20% glycerine 
10% β-mercaptoethanol 
0.004% bromphenol blue pH = 6.8 
TBST 150 mM NaCl 
50 mM Tris 
0.1% Tween20® pH = 7.4 
Transfer buffer 25 mM Tris 
150 mM glycine 
10% methanol 
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2.1.4 Kits 
Name Company 
Cell Proliferation ELISA BrdU (colorimetric) Roche Diagnostics, Mannheim, Germany 
RC DCTM Protein Assay Bio-Rad Laboratories, Hercules, CA, USA 
2.1.5 Software 
Name Version Company 
Axiovision 4.6.3 Carl Zeiss AG, Jena, Germany 
IBM SPSS Stastistics 19, 20 IBM SPSS Corporation, Chicago, IL, USA 
ImageJ 1.46r National Institue of Health, Bethesda, MD, USA 
Metamorph 7.0 Molecular Devices, Sunnyvale, CA, USA 
Photoshop CS5 Adobe Systems, San Jose, CA, USA 
Primer3 0.4.0 Whitehead Insitute of Biomedical Research, Cambridge, UK 
Microsoft Office 2003 Microsoft Corporation, Redmond, WA, USA 
2.2 Methods 
2.2.1 Cell Culture 
C2C12 mouse myoblasts (147, 148) obtained from the DSZM Braunschweig, Germany, were 
maintained in proliferation medium (PM) in T75 cell culture flasks. Cells were kept in a 
humidified incubator at 37°C and 5% CO2. Only cells not exceeding passage 6 were used in 
the experiments. 
2.2.1.1 Thawing Cells 
The freezing vial was taken out of the -150°C freezer and transported on ice. The suspension 
was thawed carefully in a 37°C water bath and transferred into a 15 mL conical tube. 9 mL of 
pre-warmed PM were added dropwise. The suspension was then centrifuged (800 g, 5 min, 
room temperature [RT]) to remove toxic dimethylsulfoxide (DMSO). The pellet was 
resuspended in fresh PM and cells were plated in T75 cell culture flasks. Before being used 
in experiments, cells were splitted at least once after thawing. 
2.2.1.2 Freezing cells 
Cells were detached at 60-70% confluence from the T75 cell culture flasks with 1 mL trypsin 
and incubated for 3 min at 37°C. The reaction was stopped by addition of 9 mL DPBS and 
cells were pelleted (800 g, 5 min, RT) followed by resuspension in freezing medium 
(approximately 1 mL freezing medium per 106 cells). Vials were placed in a pre-cooled 
freezing container and placed at -80°C. The next day vials were transferred to -150°C for 
long-term storage. 
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2.2.1.3 Splitting Cells 
At 60-70% confluency, cells were splitted to maintain the undifferentiated character. 
Therefore, the PM was aspired from the T75 cell culture flasks, cells briefly washed with 
DPBS and trypsinised with 1 mL for 3 min at 37°C. The reaction was stopped by adding 9 mL 
DPBS and centrifugation (800 g, 5 min, RT). The pellet was resuspended in fresh pre-
warmed PM and cells plated in the desired density into a new cell culture flask. 
2.2.1.4 Seeding cells 
For the experiments, cells were seeded at a density of 10.000 cells per cm2 onto cell culture 
petridishes or multi-well plates. If cells were plated on glass cover slips for subsequent 
microscopic analysis, these were pre-coated with 0.1% gelatine to ensure cell attachment 
and incubated for at least 45 min at 37°C. Just before use, the remaining gelatine solution 
was aspired and cover slips air-dried for 1-2 min. The C2C12 cells were briefly washed with 
DPBS, trypsinised and centrifuged (800 g, 5 min, RT). The pellet was resuspended in fresh 
PM and cells counted using a hemocytometer. The required resuspension volume was 
transferred into a conical tube, an adequate amount of PM was added and cells seeded into 
appropriate cell culture dishes for experimental use.  
2.2.1.5 Experimental Design 
After plating, cells were kept in PM until 80-90% confluence was reached. Thereafter, 
medium was switched to differentiation medium (DM) containing 4% horse serum. This 
serum mitogen withdrawal induces differentiation in C2C12 cells which then start to fuse and 
form myotubes (147, 149). Sodium L-lactate was added to give various concentrations La 
DM. The chosen concentrations are based on several reports from the literature. After 
vigorous exercise, blood plasma concentrations have been reported to rise to up to 25 mM. 
Intramuscular levels can rise by up to 40 mM (150–155). Usually, levels within the muscle 
are ~10 mM higher than systemic levels (156). For example, after 400 m sprinting, blood La 
concentrations are about 19 mM in sprinters, after a 3000 m run La peak was at 12 mM 
(157). Taken collectively, these data suggest that La concentrations of 10 and 20 mM are 
physiologically relevant and have therefore been previously applied in the literature (136, 
158). 
The La concentrations in the different DM were measured before each experiment and did 
not vary more than 5% from the nominal value. La DM was produced in sufficient amounts 
for the whole experiment to ensure constant incubation conditions.  
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La uptake and pH changes 
Experiments investigating the La uptake and pH changes were performed using 0, 5, 10, and 
20 mM La DM and medium samples were taken before (pre) and after 15, 30 min, 1, and 2 h 
for La sampling and before (pre) and after 2 h for pH measurement. 
Dose-dependency experiments 
For the examination of dose-dependent effects of La, cells were incubated intermittently for 2 
h at the same time each day with 0, 10, and 20 mM La DM for up to 5 days and fixed or lysed 
after the incubation phase of the respective day. Intermittent incubation was chosen to create 
a more realistic training situation where La levels are only elevated for a certain amount of 
time compared to continuous treatment. 
Involvement of oxidative stress 
Cells stained for 8-epi-prostaglandin F2α (8-epi-PGF2α) were incubated with 0 or 20 mM La 
DM as well as 20 mM La DM additionally containing the antioxidants L-ascorbic acid (AA; 
100 µm), N-Acetyl-L-cysteine (NAc; 5 mM), or linolenic acid (LA; 5 µM) and fixed immediately 
after the treatment. Cells for gene expression analysis were treated likewise, but after La 
incubation C2C12 were incubated with 0 mM La DM in all conditions for another 4 h before 
RNA was isolated. Furthermore, cells were treated with the same incubation media 
intermittently for 2 h each day at the same time for 5 days to investigate long-term effects 
and fixed or lysed immediately after the treatment on day 5. 
Involvement p38 MAPK 
Cells were treated with 0 mM or 20 mM La DM as well as 0 mM + DMSO and 0 mM + 
SB203580, a well-described p38α and p38β MAPK inhibitor (159), for 15, 30 min, 1, 4, and 
24 h. For the latter two conditions, cells were pre-incubated with SB 203580 or DMSO for 1 h 
prior to the experiment to ensure inhibition-efficiency and control for the pre-treatment, 
respectively. SB203580 is insoluble in water and is therefore dissolved in DMSO. To exclude 
effects being induced by the solvent, 0 mM + DMSO was added as an extra control 
condition. After each time point cells were lysed. To study long-term effects of this treatment, 
cells were intermittently incubated with the above mentioned media for 2 h at the same time 
each day for 5 days. Cells were then fixed or lysed after the last treatment. 
Involvement of histone modifications H3K27 me3 and H3K4me3 
C2C12 were treated with 0 or 20 mM La DM and fixed before (pre) and after 15 min, 1, and 4 
h of treatment. Additionally, long-term effects on the histone modifications were investigated 
by daily intermittent incubation for 2 h with 0 or 20 mM La DM at the same time each day. 
After the last treatment, cells were fixed. 
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All experiments were conducted in three independent runs except for gene expression 
analysis which was carried out twice. 
2.2.1.6 La and pH measurement 
La and pH in the incubation media were measured at the above mentioned time points. For 
La measurement, 20 µL incubation medium was drawn from the well using an end-to-end 
plastic capillary and mixed with 1 mL ready-to-use hemolyzing solution buffer. Samples were 
measured with a Biosen S-Line analyser in duplicates which uses an enzymatic-
amperometric test principle. pH was analysed by taking the whole media off the cells and 
measuring samples with the pH-mV-meter in duplicates. 
2.2.1.7 Bromodeoxyuridine(BrdU)-Assay 
Proliferation was in one experiment analysed using the colorimetric immunoassay for the 
quantification of cell proliferation (BrdU-based). Procedures were conducted according to the 
manufacturer’s instructions. Briefly, 1000 cells per well were seeded in a 96-well plate. After 
2 days in PM, cells were treated for 2 h with 0, 20 mM La DM, 20 mM La DM + 100 µM AA, 
20 mM La DM + 5 mM NAc, or 20 mM La DM + 5 µM LA. BrdU labelling time was 6 h. 
2.2.1.8 Gene expression analysis 
2.2.1.8.1 RNA isolation 
After treatment cells were washed with DPBS before they were lysed directly in the culture 
dish with TriReagent® (1 mL per 106 cells). Using a cell scraper the cells were detached from 
the culture dish and transferred to a 1.5 mL reaction tube. The mixture was gently mixed by 
up-and-down pipetting and incubated for 5 min at RT to allow complete dissociation of 
nucleoprotein complexes. This step was followed by -80°C storage until isolation of RNA was 
carried out. For this, samples were thawed on ice and addition of 100 µL bromochloro phenol 
(BCP) per 1 mL TriReagent® used followed. The samples were vigorously vortexed for 15 s, 
incubated for 10 min at RT, and centrifuged (12,000 g; 10 min, 4°C). Following the 
centrifugation, the mixture was separated into three phases: a red phenol-chloroform phase 
(bottom layer) and interphase (middle layer) containing DNA and protein whereas the 
aqueous phase (upper layer) contained exclusively the RNA. The aqueous layer was 
transferred into a new 1.5 mL reaction tube and an equal volume of isopropanol was added 
to precipitate the RNA which forms a gel-like or white pellet after subsequent centrifugation 
(12.000 g, 8 min, 4°C). The supernatant was discarded and the pellet washed with pre-
cooled 75% ethanol followed by thorough vortexing. The ethanol washing step repeated. 
After the last centrifugation, the supernatant was completely removed and the pellet air-dried. 
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If no remaining ethanol could be observed the pellet was dissolved in 20 µL of RNAse free 
water. 
2.2.1.8.2 RNA concentration determination and quality assessment 
Absorbance of RNA at 260 nm was measured using the NanoDropTM 1000 
spectrophotometer to determine the concentration of the sample. At a wavelength of 260 nm 
absorption of 1 corresponds to 40 µg·mL-1 RNA or 50 µg·mL-1 cDNA. The quality (purity and 
integrity) was assessed by the additionally measuring the 260/280 nm ratio and 1% agarose 
gel electrophoresis and HD Green staining. The concentration of samples was adjusted to ~1 
µg·µL-1 by adding an adequate amount of RNAse free water.  
2.2.1.8.3 Complimentary DNA (cDNA) synthesis 
The Qiagen QuantiTect® Reverse Transcription kit was used to eliminate genomic DNA and 
synthesize cDNA of samples. Procedures were carried out according to the provided 
instructions. For incubation steps the Flexcycler2 was used. 
2.2.1.8.4 Primer Design 
The genomic sequence data available at the University of California at Santa Cruz Genome 
Bioinformatics site (UCSC Genome Browser) and the web tool Primer3 (160, 161) were used 
to design primers listed in Table 2.1. Criteria applied to design primers were: primer length 
(20-25 bp), melting temperature (Tmelt; 58-60°C), amplicon length (150-250 bp). The National 
Center for Biotechnology Information’s (NCBI’s) BLAST, USCS’ BLAT, and USCS’s in silico 
PCR tool were used to check the specificity of the designed primers. 
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Table 2.1: Primers used in real-time RT-PCR 
Name Protein NM   Sequence Product size [bp]
Pax7 011039 forward 5'GCTACAGTGTGGACCCTGTG3' 229 
reverse 5'GAGACTCAGGGCTTGGGAAG3' 
Myf5 008656 forward 5'TGGTCCCGAAAGAACAGCAG3' 163 
reverse 5'AAGCTGTGTCCTGAAGAGCC3' 
MyoD 010866 forward 5'CGACACCGCCTACTACAGTG3' 214 
reverse 5'GGTCTGGGTTCCCTGTTCTG3' 
Myogenin 031189 forward 5'GTGAATGCAACTCCCACAGC3' 194 
reverse 5'GTTGGGCATGGTTTCGTCTG3' 
MHC1 30679 forward 5'CCAGGACCTTGTGGACAAAC3' 243 
reverse 5'TGGTCACTTTCCTGCACTTG3' 
MHC2 00139545 forward 5'AAGAGACAAGCTGAGGAGGC3' 249 
reverse 5'GAATCACACAGGCGCATGAC3' 
Cdkn1a p21 001111099 forward 5'TCTGAGCGGCCTGAAGATTC3' 186 
reverse 5'GAAGATGGGGAAGAGGCCTC3' 
Trp53 p53 001127233 forward 5'GCCGGCTCTGAGTATACCAC3' 184 
reverse 5'CTTCTGTACGGCGGTCTCTC3' 
Cyclophilin A 203430 forward 5'GGATTCATGTGCCAGGGTGG3' 212 
reverse 5'CACATGCTTGCCATCCAGCC3' 
All primers were purchased from Invitrogen, Karslruhe, Germany 
 
2.2.1.8.5 Quantitative real-time reverse transcription polymerase chain reaction (RT-
PCR) 
Quantitative real-time RT-PCR was performed on the thermocycler Mx3005P. The cycling 
conditions used are shown in Table 2.2. Samples were run in triplicates. 
 
Table 2.2: Cycling conditions for real-time RT-PCR 
  Cycle length T  Repititions 
PCR initial activation step 15 min 95°C 
Denaturation 15 s 94°C 
40 Annealing 30 s 58°C 
Extension 30 s 72°C 
 
 
Data was normalized to house keeping gene (cyclophilin A) and the x-fold increase was 
calculated according to (162), i.e. the following equations: 
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∆Ct = Mean Ct (gene of interest) – Mean Ct (cyclophilin A) 
∆∆Ct = ∆Ct (gene of interest) - ∆Ct (pre condition of gene of interest) 
x-fold increase = 2-∆∆Ct 
 
Random samples of RT-PCR products of each gene amplified were diluted 1:1 in TAE, run 
on a 1.5% agarose gel for 20 min at 120 V. A 100 bp DNA ladder was used to assess size of 
RT-PCR products. Comparison with product sizes predicted by the primer design programme 
followed. If a single band per gene was observed with the correct amplicon size, primer 
binding was considered specific and RT-PCR valid. 
2.2.2 Human Muscle Biopsies 
The human intervention study was co-ordinated by Dr. Sebastian Gehlert and conducted in 
close co-operation. Biopsies were taken by PD Dr. Dr. Thorsten Schiffer. 
2.2.2.1 Subjects 
15 healthy male sports students participated in the study. Prior to study participation, 
subjects were screened for health including clinical history, physical examination, laboratory 
blood tests, and an exercise electrocardiogram. The study purposely chose trained subjects 
that were involved in regular exercise and experienced in resistance training (up to twice a 
week). Participants were informed in oral and written form of the study’s purpose and the 
possible risks involved before giving written informed consent. The study was approved by 
the Ethic Committee of the German Sport University Cologne in compliance with the 
Declaration of Helsinki. Subjects were randomly assigned to one of two different exercise 
regimens: high intensity resistance training (HIT; n = 8), or standard resistance training (STD; 
n = 7). For anthropometrical data of subjects see Table 2.3. 
 
Table 2.3: Anthropological data of subjects 
Exercise group n Age [years] Height [cm] Weight [kg] 
STD 7 23 ± 3 181 ± 6 74 ± 6 
HIT 8 23 ± 4 180 ± 7 78 ± 10 
 
2.2.2.2 Experimental design and resistance training protocols 
In the 14 days before the start of the study, subjects were asked to refrain from resistance 
exercise training as well as from any physical activity in the last 48 hours prior to the baseline 
biopsy, pre-testing and the experimental trial. On the evening (10 pm) before the lab visits all 
subjects were fed a standardised protein-energy drink (contents: 20 g protein, 24.8 g 
carbohydrate, 13.4 g fat, providing 1260 kJ) and fasted overnight. The following morning 1 h 
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prior the baseline biopsy and the experimental trial, subjects were asked to drink a second 
energy drink in order to ensure the exercise being carried out in the fed state. Subjects drank 
water ad libitum during all exercise interventions.  
7 days before the actual experimental trial subjects reported to the laboratory to undergo pre-
testing in order to determine maximum dynamic eccentric and concentric force output during 
single leg extensions. All subjects were asked to warm-up for 10 min on a Lode Excalibur 
cycling ergometer with 1 W·kg-1 body mass. The testing was performed on an ISOMED 2000 
isokinetic machine with visual feedback. Subjects were seated on the isokinetic machine to 
adjust range of motion (ROM), knee-joint and lever arm axis. All participants performed a 
warm-up phase consisting of 3 sets of 4 concentric and eccentric repetitions with 90 s resting 
phase at a subjectively chosen sub-maximal intensity. After 3 min resting, subjects were 
subjected to a single set of 10 repetitions with concentric and eccentric knee extensions. 
After the first 5 sub-maximal repetitions, subjects were advised to carry out 3 maximal 
repetitions during the whole ROM in the concentric and eccentric phase. The last 2 
repetitions were carried out passively by the isokinetic machines without actively generated 
force. Due to force-length and force-angle relationship, maximum force output during 
concentric and eccentric contractions followed a hyperbolic curve. The highest maximum 
force (Fmax) achieved was applied for the experimental trial as the 100% reference curve. As 
the experimental trial differed in movement speed, pre-tests were carried out at the 
movement speed corresponding to the specific exercise mode in the experimental trial that 
each subject was assigned to. 
On the day of the actual experimental trial, subjects reported to the laboratory at 7.45 am. 
Prior to the resistance training session, the same cycle ergometer warm-up as in the pre-
testing was carried out. A combined warm-up and main exercise stimulus followed 
subsequently on the isokinetic leg extension machine. The programme was automatically 
operated by the control unit of the isokinetic device. ROM and angle velocity were 
standardized for each subject. The first phase consisted of 3 sets of 4 concentric and 
eccentric repetitions at 30% Fmax with 90 s resting in between. The angular velocity was set 
to 65°·s-1 movement speed in concentric and eccentric phases for each subject and exercise 
group. The warm-up was followed by 3 min resting before the actual exercise trial was 
conducted. 
Resistance exercise stimuli: 
Both exercise regimens were carried out as unilateral single leg extensions with 70° ROM.  
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STD: 3 sets of 10 unilateral concentric and eccentric leg extensions with 3 min rest 
between sets at 75% Fmax; movement speed 65°·s-1 with 66 s time under tension. 
 
HIT: 1 set of 20 unilateral concentric and eccentric leg extensions at 100% Fmax; movement 
speed 40°·s-1 with 70 s time under tension. 
 
All subjects of the HIT group were verbally encouraged during the exercise session to 
perform all contractions with maximum voluntary force. A visual feedback of their 100% 
reference was shown for further encouragement during each contraction.  
2.2.2.3 Muscle biopsy 
Muscle biopsies were taken from the musculus vastus lateralis of the exercised leg at 15, 30 
min, 1, 4, and 24 h post exercise. Biopsies were taken 2 cm apart from each other, so that all 
6 biopsies were collected within a range of 8-10 cm. Biopsies were obtained 2.5 cm below 
the fascia using the percutaneous needle biopsy method. Skeletal muscle biopsies were 
freed from blood and dissected from any visible fat and connective tissue. Tissue samples for 
Western blot analysis were immediately placed in cryotubes, frozen in liquid nitrogen and 
stored at -80°C until further analysis. Muscle samples for immunohistochemical staining were 
carefully aligned for cross-sectional analysis, embedded in Tissue-Tek®, frozen in liquid 
nitrogen-cooled isopentane and stored at -80°C. 
2.2.3 Protein analysis 
2.2.3.1 Western Blot (WB) Analysis 
2.2.3.1.1 Cell lysis 
Cells were washed with ice-cold DPBS and then lysed with 1 mL lysis buffer containing 
phosphatase and proteinase inhibitors using a cell scratcher. Lysates were passed through a 
hypodermic needle (0.4 x 20 mm), vortexed, and kept on ice for 20 min, thereafter 
centrifuged (10,000 g, 10 min, 4°C), the supernatant frozen in liquid nitrogen and stored at -
80°C until further analysis. The pellet contained the cell debris and was therefore disposed 
of.  
2.2.3.1.2 Homogenisation of human muscle biopsies 
20 mg of muscle tissue was homogenized in 500 µL of ice-cold ready-to-use cell lysis buffer 
using a commercially available micro-dismembrator. Homogenates were incubated on a rotor 
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at 4°C for 60 min. Centrifugation (10.000 g, 10 min, 4°C) followed and the pellet consisting of 
tissue debris was discarded. Homogenates were pooled for each group and stored at -80°C 
until further analysis. 
2.2.3.1.3 Protein concentration determination and sample preparation 
Total protein concentrations were determined using the RC DCTM Protein Assay Kit 
according to the manufacturer’s instructions. 2x Laemmli buffer (163) was added to the 
samples in an equal volume, incubated for 5 min at 95°C in a thermoblock and briefly 
centrifuged. In this step, the proteins were denatured and reduced to ensure thorough 
separation of proteins during gel electrophoresis. Samples were stored at -20°C until used 
for Western blotting. 
2.2.3.1.4 SDS-PAGE and Western Blot 
Samples were then loaded in a pre-cast CriterionTM XT 4-12% Bis-Tris gel in MOPS running 
buffer and gel electrophoresis was run until proteins were thoroughly separated. Afterwards, 
proteins were transferred onto a polyvinylidene fluoride (PVDF) transfer membrane in a 
semi-dry blotting setup for 30-40 min, applying 1 A and 25 V. To avoid unspecific binding of 
antibodies, PVDF membranes were subsequently blocked with 5% BSA or 5% dry milk 
powder (MP) in TBST, before overnight incubation with the primary antibody diluted (Table 
2.4) in 5% BSA or TBST at 4°C. The next day, membranes were thoroughly washed with 
TBST (4 intervals: 10 min, 5 min, 10 min, 5 min) and incubated with the respective HRP-
conjugated secondary antibody (1:2000 in TBST) for 60 min at RT. Another washing step 
followed (see above). Signals were detected using enhanced chemoluminescence assay 
exposed on x-ray films. Time of exposure differed between the different antibodies used (2 s 
– 30 min). It was ensured that bands were properly visible, separated and not overexposed. 
WB films were analysed and (semi-)quantified using the ImageJ software. More specific, 
films were scanned in black and white film mode, inverted to give a negative picture and 
each band was analysed for its integrated density, i.e. the product of area and average grey 
value. Bands were normalised to actin or tubulin bands. 
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Table 2.4: Antibodies used for IF/ICC and WB 
Name Species Dilution Manufacturer 
    IF/ICC WB   
Pax7 mouse 1:250 1:500 Neuromics, Edina, NM, USA 
Myf5 rabbit 1:250 1:500 GeneTex, Irvine, CA, USA 
D7F2 (MyoD) mouse - 1:500 Developmental Studies Hybridoma Bank, Iowa City, IA, USA 
F5D (Myogenin) mouse 1:250 1:500 Developmental Studies Hybridoma Bank, Iowa City, IA, USA 
Mf20 (MHC) mouse 1:500 1:100 Developmental Studies Hybridoma Bank, Iowa City, IA, USA 
MANEX mouse 1:75 - Developmental Studies Hybridoma Bank, Iowa City, IA, USA 
Ki67 rabbit 1:250 - Abcam, Cambridge, UK 
act. Casp-3 rabbit 1:500 - BD Pharmingen, Franklin Lakes, NJ, USA 
8-epi-PGF2α goat 1:1500 - Oxford Biomedical Research, Oxford, MI, USA 
p38 rabbit - 1:200 Abcam, Cambridge, UK 
p-p38 (Thr180 + Tyr182) rabbit - 1:1000 Epitomics, Burlingame, CA, USA 
H3 total rabbit 1:1000 1:1000 Cell Signaling Technology, Danvers, MA, USA  
H3K4me3 rabbit 1:1000 1:1000 Cell Signaling Technology, Danvers, MA, USA  
H3K27me3 rabbit 1:1000 - Cell Signaling Technology, Danvers, MA, USA  
Actin mouse - 1:4000 Millipore, Billerica, MA, USA 
Tubulin mouse - 1:2000 GeneTex, Irvine, CA, USA 
Alexa488 or Alexa555-
conjugated 2° antibodies
goat-anti-
rabbit or 
goat-anti-
mouse 
1:1000 - Invitrogen, Karlsruhe, Germany 
streptavidin-conjugated 
2° antibodies 
goat-anti-
rabbit or 
rabbit-anti-
goat 
1:400 - Dako, Glostrup, Denmark 
HRP-conjugated 2° 
antibodies 
goat-anti-
rabbit or 
rabbit-anti-
goat 
- 1:2000 Thermo Fisher Scientific, Waltham, MA, USA 
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2.2.3.2 Immunofluorescent staining (IF) 
2.2.3.2.1 Fixation and permeabilisation of cells 
IF staining was carried out to detect Pax7, Myf5, F5D (myogenin), Mf20 (MHC), total H3, 
H3K4me3, and H3K27me3 proteins. Unless otherwise stated all steps were carried out at 
RT. Cells were fixed by 15 min incubation with 4% paraformaldehyde followed by 3 washing 
steps with PBS. To make cells permeable for reagents and antibodies, they were treated for 
10 min with permeabilisation solution containing TritonX-100 (Tx-100) which disintegrates the 
cellular membrane due to its detergenic properties. 4 washing steps with PBS followed.  
2.2.3.2.2 Fixation of human tissue sections 
Frozen, Tissue-Tek® embedded muscle biopsies were cut into 7 µm thin sections with a 
cryostat and mounted onto Poly-L-lysine coated miscroscope slides, air dried and stored at   
-80°C until fixation by 8 min incubation with pre-cooled acetone at -80°C followed. The 
fixation solution was washed off thouroughly with TBS.  
2.2.3.2.3 Immunological detection 
Unspecific binding sites were blocked by 60 min incubation with 5% BSA in PBS for cells or 
5% BSA in TBS for tissue sections. This step was followed by primary antibody incubation at 
4°C overnight. All antibodies were diluted in 0.8% BSA in PBS or TBS for cells or tissue 
sections, respectively. For primary antibody dilutions see Table 2.4. For double staining 
(H3K4me3 or H3K27me3 and Mf20; H3K4me3 or H3K27me3 and MANEX, i.e. dystrophin) 
both antibodies were applied in the same step as they were generated in different species 
and no cross-reactivity was observed. IF controls were carried out with each IF to exclude 
autofluoroscence or any unspecific binding of the secondary antibody. These samples were 
incubated overnight at 4°C with 0.8% BSA in the respective buffer. The following day any 
unbound primary antibody was washed off with 4 buffer washing steps. The specific 
fluorochrome-conjugated secondary antibody (Table 2.4) recognizes any primary antibody 
from the respective host species and can therefore be used to label the target protein with a 
fluorescent signal. For this, cells or tissue sections were incubated for 45-60 min with the 
appropriate secondary antibody (cells: 1:1000 in PBS; tissue sections: 1:1000 in TBS) or a 
mixture of two in case of double staining as mentioned above. This was washed off again by 
4 buffer washing intervals. The cells/tissue sections were then incubated for 5 min with DAPI 
solution. DAPI is a fluorescent stain that binds strongly to A-T rich regions of the DNA and 
therefore allows marking cell nuclei. Again, samples were washed 4 times with the respective 
buffer before being mounted onto microscopic slides (cells) or covered with glass slips 
(tissue sections) using Aqua-Poly/Mount. 
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2.2.3.2.4 Microscopy and analysis 
Cover slips were photographed using a Zeiss Axiovert 200M, a MRm camera, and Axiovision 
software. In case of IF staining, the appropriate filter set for each applied fluorochrome (see 
2.1.1) was used. For every condition 20 pictures of cells with a 20x objective were taken and 
total nuclei number counted using the nucleus counter tool from ImageJ software. Ki-67, 
Pax7, Myf5, F5D or Mf20 positive nuclei were counted manually. The ratio of 
Ki67/Pax7/Myf5/F5D/Mf20 positive cells to total number of nuclei in each photograph was 
calculated. Cells treated to investigate acute and long term effects regarding histone 
trimethylations were photographed with the exact same settings (exposure time, disabled 
automatic corrections, etc. to allow for quantification of fluorescent signals) using the 63x 
objective. 20 pictures for every condition were analysed as described below. Pictures of 
human tissue sections were taken with 10x and 63x objectives. For each subject, 10 pictures 
of cross-sectional areas were taken using the 10x objective and exactly identical settings 
(see above) followed by analysis using the ImageJ software as described below. To take 
higher quality pictures using the 63x objective, an ApoTome unit was used additionally. 
2.2.3.2.5 Quantification of fluorescence 
Cover slips were analysed using a Zeiss Axiovert 200M equipped with a MRm AxioCam and 
Axiovision 4.6 software. Staining intensity was then analysed using Metamorph software. 
After a series of corrections (e.g. for background), a common threshold was set for each 
target protein in all conditions. The signal was localized in the nucleus. Therefore, the nuclei 
of all cells in the photo were (semi-)quantified for staining intensity. 
Human tissue sections were analysed using the “Analyze particles...” tool from the ImageJ 
software. Pictures with the H3K4me3 or H3K27me3 signal were converted to 8-bit, 
thresholded and inverted, the scale set to 1.6 pixel·µm-1 and analysed. The results contained 
the average area of the fluorescent signal within each nuclei corresponding to the staining 
intensity and hence, quantification of the signal. In the human study, pre levels were set to 1 
and values of subsequent time points are expressed as area change compared to pre. 
2.2.3.3 Immunocytochemistry (ICC) 
2.2.3.3.1 Fixation, permeabilisation and inactivation of endogenous peroxidase of cells 
ICC procedures for Ki67, activated Caspase-3 (act. Casp-3), and 8-epi-PGF2α were carried 
out at RT unless otherwise stated. Cells were fixed and permeabilised as described above 
(section 2.2.3.2.1). However, for cells undergoing DAB staining an incubation phase with 
0.6% hydrogen peroxide (H2O2) in 80% methanol to eliminate endogenous peroxidase 
activity followed.  
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2.2.3.3.2 Immunological detection and DAB staining 
In order to avoid unspecific binding cells were blocked with 5% BSA in PBS for 60 min. 
Primary antibodies (Table 2.4) were diluted in 0.8% BSA in PBS and cells incubated 
overnight at 4°C. ICC controls were carried out. These samples were treated with 0.8% BSA 
in PBS without any primary antibody overnight at 4°C. The next day, cells were washed 4 
times with PBS and treated with streptavidin-conjugated secondary antibody (1:400 in PBS) 
for 60 min. After 4 further washing intervals, the samples were then incubated for 60 min with 
biotinylated horse radish peroxidase (1:150 in PBS). This solution was washed off by another 
4 washing steps with PBS and DAB staining followed. For this, the DAB staining solution was 
freshly prepared, filtered and pipetted onto the cells. Staining was carried out under the 
microscope where samples were continuously compared to ICC control samples. As soon as 
staining was visible (1-15 min), the reaction was stopped by removing the DAB solution and 
washing the cells 4 times with PBS. Cells were then dehydrated by immersion of cover slips 
into a graded series of ethanol (70%, 96%, and 100%) and xylol baths and eventually 
mounted onto microscopic slides with Entellan®. 
2.2.3.3.3 Microscopy and densitometry 
DAB stained samples (act. Casp-3) were photographed using a Zeiss KS300 microscope 
equipped with a Sony CCD camera. Pictures at 20x magnifications were taken and at least 
200 cells per condition were analysed for staining intensity, i.e. average grey value, using 
ImageJ software.  
2.2.4 Statistical analysis 
Data are presented as mean ± standard error of the mean. In case of follow-up statistical 
analysis, data was tested for the normality of distribution using the Shapiro-Wilk- (small 
sample size) or the Kolmogorov-Smirnov-test (large sample size). Where appropriate, 
repeated measure analysis of variance or a one-way analysis of variance was used to test 
whether the treatment had an effect. To test differences between the groups a post-hoc 
Bonferroni test was carried out. In case of a significant result for Shapiro-Wilk or 
Kolmogorov-Smirnov-test, the Kruskal-Wallis- and Mann-Whitney-U-test were used. WB 
results were not subjected to statistical analysis. Statistical significance was set at p < 0.05. 
Analysis was carried out using SPSS Statistics for Windows. 
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3 ResultsRESULTS 
3.1 Changes in La concentration and pH in incubation media 
C2C12 cells were treated with 0, 5, 10, or 20 mM La DM for up to 2 h in order to ensure La 
uptake of the cells and control for any effects possibly induced by associated changes in pH 
(Figure 3.1). Treatment with 0 or 5 mM La DM resulted in a continuous increase in La 
concentration over the time course of the experiment. La levels in the 10 and 20 mM La DM 
decreased within the first hour of treatment indicating La oxidation. After that, incubation 
media showed increased La levels that rose higher than baseline concentrations (Figure 3.1 
A). Given that this phenomenon occurred only after the first hour of incubation, and La levels 
in vivo were shown to return to basal level not until at least 30-45 min independent of active 
or passive recovery (164), this still represents a realistic situation. The pH only marginally 
differed between the conditions (Figure 3.1 B). The pH in all incubation media dropped after 
2 h of treatment. The differences were within a range of -0.4 (20 mM La DM) to -0.6 (0 mM 
La DM). However the differences were not statistically significant and are not considered 
having an impact on the subsequently observed effects. 
 
 
Figure 3.1: Changes in La concentration and pH in incubation media. C2C12 cells were incubated with 0, 5, 10, 
20 mM La DM for up to 2 h. A La concentration changed over time in the incubation media. In 0 and 5 mM La DM 
La levels rose continuously over the time period of the experiment. 10 and 20 mM La DM La levels first decreased 
within the first hour and then rose above baseline values. B pH dropped slightly under all conditions. La – lactate; 
DM – differentiation medium. 
3.2 La reduced proliferation 
To investigate effects of La on cell proliferation, C2C12 cells were treated with 0, 10, and 20 
mM La DM and the ratios of Ki67-positive cells were analysed (Figure 3.2). Ki67 is 
expressed by cells which are in the G1/S/G2/mitotic phase of the cell cycle, but not in resting 
(G0) cells (165). Hence, it is a reliable marker of proliferating cells. After the second La 
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treatment, proliferation ratios in the treated samples decreased independently of the dose 
about 10-fold (10 mM La DM: 4.5 ± 1.7%; 20 mM La DM: 3 ± 1.5%) compared to control 
samples (0mM La DM: 48 ± 5.7%; both p < 0.001). The following days, proliferation went 
down to approximately 5% in all conditions and remained around that level until the end of 
the experiment (Figure 3.2 B). 
 
 
Figure 3.2: La suppressed proliferation of C2C12 cells. C2C12 cells were intermittently incubated with DM 
containing different La concentrations (0, 10, 20 mM) for 2 h each day for up to 5 days. The ratio of Ki67-positive 
nuclei was determined by ICC followed by microscopic imaging and manual cell counting. A Representative 
pictures of cells on D2. Arrows indicate positive/negative nuclei. B Ratio of Ki67-positive cells. After the second La 
treatment, proliferation ratios in the La treated samples decreased independently of the dose about 10-fold 
compared to control samples. The following days, proliferation went down to approximately 5% in all conditions 
and remained around that level. Data presented as mean ± S.E.M. * indicates statistical significance, i.e. p < 0.05. 
La – lactate; DM – differentiation medium; ICC – immunocytochemistry. 
 
3.3 La increased activation of Caspase-3 
Procaspase-3 is cleaved to the executioner act. Casp-3 (reviewed in (166)). It allows 
identifying cells which are undergoing an apoptotic process (programmed cell death) and can 
thus be considered a marker of cellular stress. Densitometric analysis of cells stained for act. 
Casp-3 (Figure 3.3) showed that after the first La incubation, cells treated with 20 mM La DM 
showed a significant increase in act. Casp-3 compared to control and 10 mM La DM cells (0 
Results 
 
38 
 
vs. 20 mM La DM: p = 0.004; 10 vs. 20 mM La DM: p < 0.001). On day 2, overall activation 
went down in all conditions. Still, apoptotic induction was significantly higher in both La 
conditions compared to control DM treated cells (0 vs. 10 mM La DM: p = 0.007; 0 vs. 20 mM 
La DM: p < 0.001). On day 3, apoptotic induction significantly decreased further in the 0 and 
10 mM La DM cells compared to 20 mM La DM treated cells (0 vs. 20 mM La DM: p = 0.003; 
10 vs. 20 mM La DM: p = 0.011). As from day 4, cells grew too dense and pronounced 
myotube formation made it impossible to determine act. Casp-3 levels from that time point on 
using this method. However, the conclusive result from this experiment is that La induces 
increased activation of Casp-3 in a dose dependent-manner. 
 
 
Figure 3.3: La induced cellular stress in C2C12 cells. C2C12 cells were intermittently incubated with DM 
containing different La concentrations (0, 10, 20 mM) for 2 h each day for up to 3 days. Act. Casp-3 was 
densitometrically quantified as a protein marker for the induction of apoptotic signalling, i.e. cellular stress. Data 
presented as mean ± S.E.M. * indicates statistical significance, i.e. p < 0.05. La – lactate; DM – differentiation 
medium; act. Casp-3 – activated Caspase-3. 
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3.4 La timely delayed late differentiation in a dose-dependent manner 
C2C12 cells were intermittently incubated with DM containing different physiologically 
relevant La concentrations (10, 20 mM) over a time period of 5 days simulating a microcycle 
of high intensity endurance training. A screen of samples using WB analysis implied a dose-
dependent La effect on several differentiation markers (Figure 3.4). The higher the La 
concentration in the DM the higher the Pax7 content in the respective samples. No obvious 
differences could be detected for Myf5 and MyoD. Conversely, markers of late differentiation, 
i.e. myogenin and MHC, are expressed less the higher the La content in the DM (Figure 3.4 
B). 
 
 
Figure 3.4: La delayed the differentiation process of C2C12 cells in a dose-dependent manner. C2C12 cells were 
intermittently incubated with DM containing different La concentrations (0, 10, 20 mM) for 2 h each day for 5 days. 
Western Blot analysis showed that markers of activation and early differentiation (Pax7) are more abundant in La-
treated samples, whereas late differentiation markers (myogenin, MHC) are found to be less abundant. Myf5 and 
MyoD appeared unchanged. A Representative blots for Pax7, Myf5, MyoD, Myogenin, and MHC. Actin was used 
as a loading control. B Quantitative analysis of WBs. Data are presented as mean ± S.E.M. La – lactate; DM – 
differentiation medium; Pax7 – paired box transcription factor 7; Myf5 – myogenic factor 5; MyoD – myogenic 
determination protein; MHC – myosin heavy chain; WB – Western Blot. 
 
Myogenin is a marker for the onset of the end-terminal differentiation of myoblasts. The ratio 
of myogenin-positive nuclei in differentiating C2C12 cells was determined using ICC (Figure 
3.5 A + B and appendix Table A.1). Number of myogenin-positive nuclei rose quickest in the 
0 mM La DM cells, peaking on day 4 of the experiment. The same level was reached when 
cells were treated with 10 mM La DM, but not until day 5. Myoblasts treated with 20 mM La 
did not reach that level at all during the 5 days of the experiment. WB results generally 
support the findings from the ICC (Figure 3.5 C). 
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Figure 3.5: La delayed myogenin synthesis in C2C12 cells. C2C12 cells were intermittently incubated with DM 
containing different La concentrations (0, 10, 20 mM) for 2 h each day for up to 5 days. IF and WB analysis 
showed that myogenin occured earlier in control than in La-treated samples. Additionally, 10 mM La DM samples 
showed earlier myogenin occurrence than 20 mM La DM treated cells. A Representative photographs of 
myogenin (green) staining on the respective days. B Ratio of myogenin-positive cells on the respective days. C 
Representative WB for myogenin and tubulin. Data presented as mean ± S.E.M. * indicates statistical 
significance, i.e. p < 0.05. La – lactate; DM – differentiation medium; IF – immunofluorescent staining; WB – 
Western blot. 
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MHC is part of the sarcomeric structure of skeletal muscle and occurs with the end-terminal 
differentiation of myoblasts into functional myotubes (167). Here, a pronounced 
concentration-dependent effect was observed (Figure 3.6 A + B and appendix Table A.2). 
MHC was detected on D2 in the control and 10 mM La DM incubated cells, but not in the 20 
mM La DM treated samples. Furthermore, 10 mM La DM resulted in significantly less nuclei 
lying within MHC-positive myotubes compared to the 0 mM La DM condition. The same 
pattern was found on D3. As from D4 on, no differences between the 0 and 10 mM La DM 
treated samples could be observed. 20 mM La DM samples showed significantly less nuclei 
within myotubes compared to 0 and 10 mM La DM on all days of the experiment. Again, 
results from the protein analysis via WB generally underline these results (Figure 3.6 C). 
After 10 days of incubation with 20 mM La DM cells were differentiated to the same extent as 
0 and 10 mM La DM cells on D5 (data not shown as 0 and 10 mM La DM treated cells 
started to dedifferentiate and detach). Summarizing these data, La treated-samples exhibited 
timely delayed late differentiation in a dose-dependent manner. 
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Figure 3.6: La delayed MHC synthesis in C2C12 cells in a dose-dependent manner. C2C12 cells were 
intermittently incubated with DM containing different La concentrations (0, 10, 20 mM) for 2 h each day for up to 5 
days. IF and WB analysis showed that MHC occurs earlier in control than in La-treated samples. A dose-
dependent effect could also be observed. A Representative photographs of MHC (green) and DAPI (blue) 
staining on the respective days. B Ratio of MHC-positive myonuclei on the respective days. C Representative WB 
for MHC and tubulin. * indicates statistical significance, i.e. p < 0.05. La – lactate; DM – differentiation medium; IF 
– immunofluorescent staining; WB – Western blot; MHC – myosin heavy chain. 
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3.5 Lactate increased oxidative stress 
A previous study suggested that the La effects are at least partly transduced within the cell 
by the shift of the redox potential, increased ROS production, and subsequent activation of 
MAPKs (136). To further elucidate this assumption cells were treated with 0, 20 mM La DM, 
and 20 mM La DM additionally containing different antioxidants and stained for 8-epi-PGF2α. 
This molecule is formed by a free radical-mediated, non-enzymatic peroxidation of 
arachidonic acid in membrane phospholipids and therefore a reliable marker to assess 
oxidative stress (168). 8-epi-PGF2α was formed under all experimental conditions (Figure 
3.7). However, 20 mM La DM showed by far the highest staining intensity whereas the 
addition of antioxidant agents led to control (LA) or lower (AA, NAc) levels of 8-epi-PGF2α. 
If the La effects are induced by the generation of ROS, the decrease in proliferation and the 
delaying effect on the late differentiation of myoblasts should be at least reduced, if not 
annihilated by the addition of antioxidants to the La DM. To test this hypothesis, BrdU 
incorporation, gene expression and protein synthesis were examined. 
 
 
 
Figure 3.7: La increased oxidative stress. C2C12 cells were treated with 0, 20 mM La DM, 20 mM La DM + 100 
µM AA, 20 mM La DM + 5 mM NAc, or 20 mM La + 5 µM LA for 2 h. Immediate fixation and follow up ICC staining 
of treated cells for 8-epi-PGF2α as a marker of oxidative stress revealed that cells treated with 20 mM La DM 
were exposed to high levels of oxidative stress. This effect was negated when antioxidants were added to the 20 
mM La DM. A Representative photographs of stained cells. B Staining intensity of 8-epi-PGF2α-stained cells. 
Data presented as mean ± S.E.M. * indicates statistical significance, i.e. p < 0.05, compared to all other 
conditions. # indicates statistical significance compared to all other conditions except 20 mM La + 5 µM LA. § 
indicates statistical significance compared to 20 mM La DM and 20 mM La DM + 100 µM AA. La – lactate; DM – 
differentiation medium; AA – ascorbic acid; NAc – N-Acetyl-L-cysteine; LA – linolenic acid; ICC – 
immunocytochemistry; 8-epi-PGF2α – 8-epi-prostaglandine F2α. 
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Figure 3.8: La-induced cell cycle withdrawal was reversible by different antioxidants. C2C12 cells were treated 
with 0, 20 mM La DM, 20 mM La DM + 100 µM AA, 20 mM La DM + 5 mM NAc, or 20 mM La + 5 µM LA for 2 h. 
A BrdU assay was performed and results showed a drop in BrdU-positive cells which was reversed by the 
addition of different antioxidants to the 20 mM La DM. Data presented as mean ± S.E.M. * indicates statistical 
significance, i.e. p < 0.05. La – lactate; DM – differentiation medium; AA – ascorbic acid; NAc – N-Acetyl-L-
cysteine; LA – linolenic acid; BrdU – bromodeoxyuridine. 
 
A BrdU assay was performed to investigate the reversibility of the La-induced decrease in 
proliferation by different antioxidants. Results clearly show that a single 20 mM La DM 
administration significantly reduces proliferation rate of myoblasts (Figure 3.8) compared to 
all other conditions (0 vs. 20 mM La DM: p = 0.02; 20 mM La DM vs. 20 mM La DM + AA: p = 
0.018; 20 mM La DM vs. 20 mM La DM + NAc: p = 0.031; 20 mM La DM vs. 20 mM La DM+ 
LA: p = 0.015) confirming the results from Ki67 analysis and demonstrating that AA, NAc, 
and LA were indeed able to reverse the La effect on proliferation behaviour. These results 
were furthermore supported by the gene expression analysis of cell cycle control genes 
transformation related protein 53 (Trp53; Figure 3.9 A and appendix table A.3) and the 
cyclin-dependent kinase inhibitor 1a (Cdkn1a; Figure 3.9 B and appendix table A.3). Trp53 
encodes the p53 protein, which is generally a regulator of cell development and 
differentiation. Specifically in myoblasts, p53 increases retinoblastoma (pRb) gene 
expression. pRb can co-operate with MyoD to transcribe later markers of differentiation (169) 
but it does not affect cell cycle withdrawal (170, 171). The Cdkn1a gene encodes the p21 
protein. p21 is an important regulator of cell cycle withdrawal during myogenesis. It leads to 
pRb hypophosphorylation which is associated with cell quiescence or differentiation 
compared to the hyperphophorylated state which is more abundant in proliferating cells (172, 
173). Trp53 expression decreased in all conditions compared to pre. However, La treatment 
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did not reveal an effect on its expression, whereas AA and LA induced elevated expression. 
In contrast, Cdkn1a expression was significantly increased by 20 mM La DM compared to 
pre and 0 mM La DM. This effect was however not reversible by the addition of antioxidants. 
 
 
Figure 3.9: La altered gene expression of cell cycle control genes Cdkn1a and Trp53. C2C12 cells were treated 
with 0 mM, 20 mM La DM, 20 mM La DM + 100 µM AA, 20 mM La DM + 5 mM NAc, or 20 mM La + 5 µM LA for 2 
h. After further 4 h incubation with 0 mM La DM RNA was isolated. Results from quantitative real-time RT-PCR 
showed A decreased Trp53 expression in all samples independent of treatment compared to the pre situation, 
whereas B Cdkn1a expression increased in the La-treated samples. Data presented as mean ± S.E.M. * indicates 
statistical significance, i.e. p < 0.05. La – lactate; Cdkn1a – cyclin-dependent kinase inhibitor 1a; Trp53 – 
transformation related protein 53; DM – differentiation medium; AA – ascorbic acid; NAc – N-Acetyl-L-cysteine; LA 
– linolenic acid; RNA – ribonucleic acid; RT-PCR – reverse transcription polymerase chain reaction. 
 
Gene expression of Pax7, Myf5, myogenin and MHC following a single La incubation bout 
were also examined (Figure 3.10 and appendix Table A.4). Expression levels before (pre) 
start of the experiment were considered baseline levels and were used as the control in the 
calculation of ∆∆Ct. Pax7 expression (Figure 3.10 A) was significantly down-regulated by La 
treatment compared to all other conditions. AA increased Pax7 mRNA levels significantly 
compared to pre, 0, and 20 mM La DM. Myf5 expression (Figure 3.10 B) was also 
significantly decreased by 20 mM La DM, but only compared to 20 mM La + antioxidative 
treatment. The increase of myogenin expression (Figure 3.10 C) in 0 mM La DM cells was 
attenuated by the addition of 20 mM La DM. Further addition of antioxidant substances 
restored myogenin expression to 0 mM La DM levels. MHC1 expression appeared to be 
lower under La conditions (Figure 3.10 D), differences were nevertheless only significant for 
0, 20 mM La DM + NAc, and 20 mM La DM + LA. The same observation was made for 
MHC2 (Figure 3.10 E). Although mRNA levels seemed to increase after DM treatment, 
differences were only significant for 20 mM La DM + AA if compared to pre and 20 mM La 
DM. Taken collectively, the addition of La to the DM significantly decreases mRNA levels of 
muscle-specific genes. 
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Figure 3.10: La influenced gene expression of Pax7, Myf5, myogenin, MHC1, and MHC2. C2C12 cells were 
treated with 0, 20 mM La DM, 20 mM La DM + 100 µM AA, 20 mM La DM + 5 mM NAc, or 20 mM La + 5 µM LA 
for 2 h. After another 4 h in 0 mM La DM RNA was isolated. Results from quantitative real-time RT-PCR showed 
altered gene expression of A Pax7 * indicates statistical significance, i.e. p < 0.05 compared to all other 
conditions. # indicates statistical significance, i.e. p < 0.05, compared to all other conditions except 20 mM La DM 
+ 5 mM NAc. B Myf5 * indicates statistical significance, i.e. p < 0.05, compared to 20 mM La DM + 100 µM AA, 20 
mM La DM + 5 mM NAc, and 20 mM La + 5 µM LA. C Myogenin * indicates statistical significance, i.e. p < 0.05, 
compared to all other conditions except 20 mM La DM. # indicates statistical significance, i.e. p < 0.05, compared 
to 20 mM La DM + 100 µM AA, 20 mM La DM + 5 mM NAc, and 20 mM La + 5 µM LA. D MHC1 * indicates 
statistical significance, i.e. p < 0.05, compared to all other conditions except 20 mM La DM. # indicates statistical 
significance, i.e. p < 0.05, compared to 20 mM La DM + NAc and 20 mM La DM + LA. E MHC2 * indicates 
statistical significance, i.e. p < 0.05, compared to pre and 20 mM La DM. La – lactate; Pax7 – paired box 
transcription factor 7; Myf5 – myogenic factor 5; MHC – myosin heavy chain; DM – differentiation medium; AA – 
ascorbic acid; NAc – N-acetylcysteine; LA – linolenic acid; RNA – ribonucleic acid; RT-PCR – reverse 
transcription polymerase chain reaction. 
 
Furthermore, results from the experiments investigating the differentiation effects on protein 
level (Figure 3.11 and appendix table 5) show that C2C12 cells treated with 20 mM La DM 
elicited a significantly higher ratio of Pax7-positive nuclei than control treatment (Figure 3.11 
C). This effect was annihilated by the addition of AA to the 20 mM La DM. However, the 
lower ratio of Pax7-positive cells was not significant for 20 mM La DM + NAc and 20 mM La 
DM + LA. Overall, these findings were confirmed using WB analysis (Figure 3.11 D). Less 
clear are the results of Myf5 investigation. Overall, a tendency for a La effect can be seen in 
ICC and WB (Figure 3.11 E + F), but the differences were only significant between 20 mM La 
DM and 20 mM La DM + AA treatment in the ICC. The most distinct results were attained 
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from the myogenin and MHC staining. Here, the La effect was clearly observed in the 20 mM 
La DM incubated cells where compared to control conditions the number of myogenin- and 
MHC-positive cells was significantly reduced. This effect was completely reversed by all of 
the applied antioxidants in both the ICC (Figure 3.11 G + I) and the WB (Figure 3.11 H + J). 
 
 
 
Figure 3.11: La-induced delayed differentiation in C2C12 cells was reversible by the use of antioxidants. C2C12 
cells were treated with 0 or 20 mM La DM or 20 mM La DM + 100 µM AA, 20 mM La DM + 5 mM NAc, 20 mM La 
+ 5 µM LA for 5 days followed by IF (ratios of marker-positive nuclei) or WB analysis. Briefly, 20 mM La DM 
treated samples contained more Pax7 and Myf5 (early differentiation markers) and less myogenin and MHC (late 
differentiation markers). These effects were mostly reversible by the addition of different antioxidants to the cell 
culture medium. A MHC- (green) and DAPI-staining (blue) in C2C12 myoblasts before (pre) and after 5 days of 
incubation with the respective DM. B Representative WBs for Pax7, Myf5, myogenin, and MHC. Tubulin was used 
as a loading control. C-J: Ratios of positive nuclei as analysed from IF (C, E, G, I) and quantification of WBs (D, 
F, H, J) for Pax7 (C, D), Myf5 (E, F), myogenin (G, H), and MHC (I, J). Data presented as mean ± S.E.M. * 
indicates statistical significance, i.e. p < 0.05, compared to the indicated experimental group (bars). If no bars are 
shown then significance is given to all other experimental groups. La – lactate; DM – differentiation medium; IF – 
immunofluorescent staining; WB – Western blot, Pax7 – paired box transcription factor 7; Myf5 – myogenic factor 
5; MHC – myosin heavy chain; AA - ascorbic acid, NAc - N-Acetyl-L-cysteine, LA - linolenic acid. 
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Figure 3.12: La has acute effects on p38 MAPK phosphorylation and H3K4 and H3K27 trimethylation. C2C12 
cells were incubated with 0 and 20 mM La DM for up to 24 h. Cells were lysed and analysed for p-p38 and 
H3K4me3 using WB techniques or fixed and stained for H3K4me3 or H3K27me3 (green) using IF. Nuclei were 
counterstained with DAPI (blue). Fluorescence was quantified using Metamorph Software. A Representative WBs 
for p-p38, total p38, H3K4me3, total H3, and actin as a loading control. B Quantification of WB results showed 
decreased p-p38 levels with La-treatment. C Quantification of WBs results revealed diminished HK4me3 with la-
incubation. D Representative pictures and staining intensity of H3K4me3. H3K4me3 staining intensity was 
significantly reduced by La-incubation after 15 min compared to control cells. E Representative pictures and 
staining intensity of H3K27me3. H3K27me3 staining intensity was significantly reduced at 1 and 4 h of La-
incubation compared to control cells. Data presented as mean ± S.E.M. * indicates statistical significance, i.e. p < 
0.05. La – lactate; DM – differentiation medium; H3Kxme3 – trimethylated histone 3 at lysine x; IF – 
immunofluorescent staining; WB – Western blot; p-p38 – phosphorylated p38 mitogen-activated protein kinase. 
3.6 Involvement of p38 MAPK and histone modifications in vitro 
 
Western Blot analysis showed a pronounced phosphorylation of p38 MAPK at Threonin 180 
and Tyrosin 182 (p-p38) after switching from PM to 0 mM La DM. Interestingly, this effect 
was abolished by the addition of 20 mM La to the DM (Figure 3.12 A + B). Therefore, an 
experiment was designed to elucidate the question whether the La effect is p38-dependent 
and effects are the same if p38 is inhibited by SB203580 added to 0 mM La DM. For this, 
cells were incubated intermittently for 5 days with 0 mM, 0 mM + DMSO, 0 mM + 10 µM 
SB203580, and 20 mM La DM (Figure 3.13 and appendix Table 6). Results revealed no 
effect of DMSO addition to the DM compared to 0 mM La DM. In contrast, IF analysis 
showed that addition of SB203580 or 20 mM La lead to increased number of Pax7 positive 
cells (Figure 3.13 C). This result was confirmed using WB (Figure 3.13 B + D) which showed 
increased Pax7 content in cell lysates of 0 mM La DM + SB203580 and 20 mM La DM cells. 
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The same observations were made for Myf5 protein content. IF showed a pronounced 
increase of Myf5 positive cell number and WB analysis of cell lysates also showed increased 
Myf5 content when cells were treated with SB203580 or 20 mM La DM (Figure 3.13 E + F). 
For later differentiation proteins myogenin and MHC higher contents of protein were found in 
0 mM La DM and 0 mM La DM + DMSO by IF and WB (Figure 3.13 A, B, G – J). Taken 
collectively, La treatment led to an increase in early differentiation proteins and decrease of 
late differentiation markers. DMSO had no effect, whereas SB203580 exhibited the same 
results as obtained from 20 mM La DM incubation. These results imply that La inhibits p38 
and its pro-myogenic effect. 
 
 
Figure 3.13: La-induced delayed late differentiation in C2C12 cells is similar to p38 MAPK-inhibition in cells 
treated with 0 mM La DM + SB203580. C2C12 cells were treated intermittently with 0 or 20 mM La DM or 20 mM 
La DM + 0.1% DMSO, 0 mM La DM + 10 µM SB203580 or 20 mM La DM for 5 days followed by IF (ratios of 
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marker-positive nuclei) or WB analysis. Briefly, 0 mM La DM + SB 203580 and 20 mM La DM treated samples 
contained more Pax7 and Myf5 (early differentiation markers) and less myogenin and MHC (late differentiation 
markers) compared to control samples A Myogenin- (green) and DAPI-staining (blue) in C2C12 myoblasts before 
(pre) and after 5 days of incubation with the respective DM. B Representative WBs for Pax7, Myf5, myogenin, 
and MHC. Actin was used as a loading control. C, E, G, I Ratio of positive nuclei from analysis of the IF. D, F, H, J 
quantification of WBs for Pax7 (C, D), Myf5 (E, F), myogenin (G, H), and MHC (I, J). Data presented as mean ± 
S.E.M. * indicates statistical significance, i.e. p < 0.05. For every marker analysed, differences between 0 mM La 
DM/0 mM La DM + DMSO and 0 mM La DM + SB203580/20 mM La DM were always significant. The former two 
were never statistically different from each other, nor were the later two. La – lactate; p38 MAPK – p38 mitogen-
activated protein kinase; DM – differentiation medium; IF – immunofluorescent staining; WB – Western blot, Pax7 
– paired box transcription factor 7; Myf5 – myogenic factor 5; MHC – myosin heavy chain. 
 
Histone modifications play an important role in gene expression regulation. Therefore, 
samples were analysed for the relevant histone modifications H3K27me3 and H3K4me3 
(Figure 3.12). The quantification of IF stained cells showed a significant lower H3K27me3 
signal in 20 mM La DM treated samples after 1 and 4 h (both p < 0.001) compared to 0 mM 
La DM (Figure 3.12 E). Notably, the H3K4me3 signal, an important downstream target of p38 
activation, follows the same timely pattern as the p38 phosphorylation (Figure 3.12 A + C). 
Results showed an increase in H3K4me3 in control samples after 30 min and reduction to 
baseline levels after 24 hours. The La-treated cells did not exhibit an increase, but the signal 
decreased over time and was not detectable at all after 24 h using WB technique (Figure 
3.12 C). Closer investigation of the trimethylated H3K4 by IF and quantification revealed an 
increase in the H3K4me3 signal after 15 min in the control but not in La samples (p = 0.002; 
Figure 3.12 D + E). Although control cells showed higher staining intensity after 1 and 4 h 
compared to 20 mM La DM cells, the differences were not statistically significant. Hence, the 
staining intensity does not differ between control and La-treated samples. Given the results 
from the WB where a decrease of the H3K4me3 signal was observed, it has to be concluded 
that the number of nuclei with the modification decreases following La incubation but not the 
intensity, and therefore the abundance of the epigenetic mark within a single nuclei. 
Collectively, these data show that a single 20 mM La DM incubation bout decreases 
H3K27me3 and H3K4me3 observed after 0 mM La DM exposure. 
Repeated exposition to 20 mM La for 2 h daily for 5 days did not elicit any differences in 
H3K27me3 compared to 0 mM La DM (Figure 3.14 A). However, overall trimethylation went 
down in myotubes compared to myoblasts independent of La. In contrast, 20 mM La DM 
significantly decreased H3K4me3 in myoblasts (p = 0.002) and in myotubes (p < 0.001) 
compared to 0 mM La DM treated cells (Figure 3.14 B). Therefore, the results indicate a 
strong influence of La on H3K4me3 by repeated exposure during differentiation, but not on 
H3K27me3. 
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Figure 3.14: La did not affect H3K27me3, but decreased H3K4me3 during differentiation. C2C12 cells were 
intermittently incubated with 0 and 20 mM La DM for 2 h each day for 5 days. IF for H3K27me3 (A; red) or 
H3K4me3 (B; red), MHC (green); and DAPI (blue) followed. A Overall H3K27me3 was down-regulated in 
myotubes compared to myoblasts, but there was no difference between the control (0 mM La DM) and 20 mM La 
DM treated cells. B H3K4me3 remained unchanged under control (0 mM La DM) conditions between myoblasts 
and myotubes, whereas 20 mM La DM decreased H3K4me3 substantially. Data presented as mean ± S.E.M. * 
indicates statistical significance, i.e. p < 0.05. La – lactate; H3Kxme3 – trimethylated histone 3 at lysine x; DM – 
differentiation medium; IF – immunofluorescent staining; MHC – myosin heavy chain. 
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3.7 p38 MAPK and histone modifications in vivo 
Obtained cell culture results were confirmed using a human exercise model where HIT was 
compared to STD training (Figure 3.15). WB analysis of muscle biopsy homogenates 
showed a slightly increasing phosphorylation of p-p38 at 15, 30 min and 1 h post STD 
training compared to the pre-situation (Figure 3.15 D). After 4 h the signal decreased, before 
reaching baseline levels at 24 h post exercise. The HIT group displayed a prominent 
dephosphorylation of p38 MAPK up to 30 min after the intervention. Then the 
phosphorylation of p38 MAPK increased at 1, 4, and 24 h post exercise, respectively. 
Furthermore, muscle homogenates were analysed for H3K4me3 (Figure 3.15 D). In the STD 
group H3K4me3 content peaked 30 min post exercise, but was not detectable at 4 and 24 h 
post exercise. In contrast, in the HIT group the trimethylation of H3K4 was diminished at 15 
min after exercise.  
Analysis of fixed muscle sections stained for H3K27me3 showed a strong decrease in 
H3K27me3 following STD whereas HIT exhibited a pronounced increase of this 
trimethylation, resulting in a significant difference 4 h post intervention (p < 0.001; Figure 
3.15 B). The opposite results were obtained for H3K4me3 (Figure 3.15 A + C). Here, 
H3K4me3 increased after the STD bout and decreased following HIT. The difference here 
was also significant (p = 0.004). Conclusively, these data show a strong influence of training 
intensity on p38 MAPK activation and subsequent H3K4me3 and H3K27me3 in human 
skeletal muscle. 
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Figure 3.15: HIT dephosphorylates p38 MAPK and diminishes H3K4me3 and H3K27me3 compared to STD. 
Subjects conducted either a STD or HIT followed by muscle biopsies at 15, 30 min, 1, 4, and 24 h post exercise. 
Human skeletal muscle tissue was homogenized and pooled for each group for WB analysis for p-p38 and 
H3K4me3. Furthermore, one part of the sample was cut into sections followed by IF for H3K4me3 and 
H3K27me3. A Representative photographs of human muscle biopsy sections stained for H3K4me3 (red), 
dystrophin (MANEX; green) and DAPI (blue) before (pre) and after (4 h post) STD or HIT exercise intervention.   
B Quantification of the average area of the H3K27me3 signal in nuclei in human muscle biopsies pre and 4 h post 
STD or HIT training. C Quantification of the average area of the H3K4me3 signal in nuclei in human muscle 
biopsies pre and 4 h post STD or HIT training D Representative Western Blots for p-p38, total p38, H3K4me3 of 
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human muscle homogenates pre and after up to 24 h post exercise. Data presented as mean ± S.E.M. * indicates 
statistical significance, i.e. p < 0.05. HIT – high intensity resistance training; p38 MAPK – p38 mitogen-activated 
protein kinase, p-p38 – phosphorylated p38 MAPK; H3Kxme3 – trimethylated histone 3 at lysine x; STD – 
standard resistance training. 
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4 DiscussionDISCUSSION 
 
The first aim of this study was to establish the phenotypical changes of intermittent La 
incubation, thereby simulating a training microcycle of resistance or high intensity endurance 
training, on the proliferation and differentiation behaviour in a strong model of skeletal muscle 
stem cells (174), namely C2C12 cells, for their essential contribution to hypertrophy (175, 
176) and regeneration (for a review, see (177)). 
Serum deprivation in cell culture experiments leads to changes in cell cycle regulators (178) 
and eventually to permanent withdrawal from the cell cycle (149, 179), an event necessary to 
induce early differentiation. Data from the Ki67-analysis and the BrdU assay show that 
proliferation in La DM-treated cells is much lower. This finding is further in line with the 
observation that Cdkn1a mRNA was more abundant in La-samples. The Cdkn1a gene 
encodes p21 which is an important regulator of cell cycle withdrawal during myogenesis. It 
leads to pRb hypophosphorylation, a state associated with differentiation rather than 
proliferation (172, 173). Trp53 encodes for the p53 protein, another important cell cycle 
regulator. Trp53 expression was not altered by La treatment. Although p53 has been shown 
to regulate p21, this is not contradictory to increased Cdkn1a expression. pRb 
hypophosphorylation by p21 was shown to be p53-independent (180, 181). and p53 was 
demonstrated to not necessarily contribute to cell cycle withdrawal in myoblasts (170, 171). 
p53 can be involved in differentiation progress. It induces pRb expression which 
subsequently associates with MyoD and activates expression of markers of late 
differentiation (169). Here, all treatments led to a decrease in Trp53 transcripts and in some 
samples late differentiation markers were nevertheless expressed. This might be explained 
by the finding that p53-requirement can be overcome by cell-cell contacts (169). In La-
treated samples proliferation went down. Possibly cell density was hence not sufficient to 
overcome p53-requirement. Conclusively, these data reveal that La enhances the serum-
deprivation induced cell cycle withdrawal. The indicated mechanism is increased Cdkn1a 
expression, and possibly successively higher p21 content. However, analysis of p21 and p53 
protein abundance and phosphorylation status of pRb is indispensable to confirm this notion. 
During myogenesis, differentiation progression is marked by cell cycle withdrawal and 
decrease of Pax7 expression. Another prerequisite is low Myf5 and elevated MyoD levels 
(149) when cells withdraw from the cell cycle during the gap 1 (G1) phase to undergo 
differentiation (182). These requirements are met by cells treated with La indicating their 
early differentiation. However, expression of late differentiation markers myogenin, MHC1 
and MHC2 was significantly decreased by La treatment indicating blocked differentiation 
progression. Furthermore, after 5 days of intermittent incubation Pax7 and Myf5 protein 
levels were increased. Pax7 protein represses myogenic progression in C2C12 myoblasts 
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(77, 167, 183, 184) and other models of muscle stem cells (184–186). Additionally, Myf5 is 
expressed in cells that remain undifferentiated although differentiation was induced (149). 
Myogenin is required to proceed to end-terminal differentiation and expression of muscle 
specific genes, such as MHC (48, 49). These findings conclusively suggest that La-treated 
cells are arrested in a quiescent state with retained potential to undergo proliferation or 
differentiation dependent on further cues. A limitation of this study is the missing data on 
MyoD. Myf5 and MyoD have contrasting transient levels during cell cycle progression. This 
includes their phosphorylation and subsequent degradation during the mitotic (Myf5) or 
G1/synthesis (MyoD) phase of the cell cycle (149, 174, 187). Analysis of MyoD might deliver 
conclusive information of the state and/or cell cycle phase that cells are arrested in and 
whether MyoD levels are also affected by La. Taken together, La inhibits one or more events 
which are essential for progression to late differentiation. This suggests that these events are 
regulated by the metabolic environment. 
The results from experiments investigating the dose-effect relationship of La on 
differentiation progress suggests that its effect is dose-dependent for at least some 
observations, i.e. apoptotic signalling induction and late differentiation, but not necessarily for 
cell cycle withdrawal. This is not surprising as these phenomena are regulated by several 
independent pathways. More experiments are nonetheless necessary to shed light on this 
topic and investigate especially how exactly the expression of late markers like myogenin 
and MHC is inhibited by La to explain the dose-dependent phenomena. 
 
The second aim of the study was to investigate whether the La effects are induced by the 
formation of ROS and hence, oxidative stress. The results clearly demonstrate increased 8-
epi-PGF2α levels following 20 mM La DM incubation, indicating ROS production. 
Furthermore, the observations from the experiments reveal that La-induced ROS formation 
can be reversed by the use of antioxidant substances. Notably, the areas around the nuclei 
were mostly affected by oxidative stress. This coincides with the localisation of highest 
mitochondrial density. It is therefore additionally argued that La leads to increased ROS 
formation within the mitochondrial membranes. This notion is further supported by the finding 
that AA and NAc showed the highest efficacy of ROS scavenging. Both antioxidative 
substances in contrast to LA unfold their direct antioxidative capacity mainly in the 
mitochondria (188–192). AA and NAc were both able to reduce oxidative stress even below 0 
mM La DM, and hence control levels. The mechanism by which LA deploys its antioxidative 
capacity remains elusive, but it has been described to act via the upregulation of the 
antioxidative enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx), and 
catalase (Cat) (193) which suggests a time-delayed and therefore weakened effect for the 
time period observed in this experiment. Nevertheless, further experiments are necessary to 
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provide clear evidence of the idea that mitochondrial ROS generation is essentially elevated 
by La. 
The formation of ROS induced by La is controversially discussed in the literature. On the one 
hand, it was shown to be capable of ROS scavenging in the absence of cells (194–196). 
Whereas this finding was shown to be also present in cultured hepatocytes (195), a 
protective effect was not established in neuronal precursor cells (196). In contrast, other 
studies demonstrated that La increases the formation of ROS. One report describes the La-
dependent enhancement of ·OH generation by the Fenton-reaction in a cell-free model (197). 
Another study found an increased production of H2O2 in L6 myoblasts by 20 mM La 
incubation indicating increased oxidative stress which is in agreement with our findings (136). 
Additionally, the results for act. Casp-3 imply that La is able to induce apoptotic events, i.e. 
cellular stress. Whereas no data on the ability of La to induce the apoptotic pathway in 
C2C12 exists, ROS are able to initiate apoptotic signalling and programmed cell death in this 
type of cells (198–200). The obtained results unambiguously reveal that with La exposure the 
oxidative stress increases within C2C12 cells. The rise in cleaved act. Casp-3 is therefore 
not surprising and provides further evidence for the conclusion that La induces cellular 
stress, marked by the increased generation of ROS and apoptotic signalling induction. 
ROS can modulate numerous processes. For example, cell cycle control is sensitive to 
oxidative stress. In several tissues and cell lines p21 mRNA increases in response to 
oxidative stress (201–203). Further research revealed that this elicits a cytoprotective effect 
via the induction of cell cycle arrest and allowing time for DNA repair in response to oxidative 
damage (204). However, one study found decreased levels of p21 following increased ROS. 
The experimental model applied was electron transportchain deficient HeLa cells that 
furthermore lack normal p53 signalling, a main regulator of p21 (205) indicating that these 
results are neglectable in the here reported context. 20 mM La DM treatment increased gene 
expression of Cdkn1a. This effect was reversible by the addition of antioxidants, further 
supporting the notion of ROS-induced p21 gene expression induction. 
As many cellular processes were shown to be ROS-sensitive, if La treatment acutely 
increases ROS formation and chronically to the initiation of early but a delay in late 
differentiation, one might consider a link between these events. In order to investigate this 
hypothesis, different antioxidants were added to the incubation medium. Results provide 
strong evidence that the La-effects depend on the formation of ROS as the outcomes were 
reversible by the use of AA, NAc, and LA. Although no data is available on the effects of La 
on C2C12 differentiation, numerous studies exist elucidating the question of how ROS 
influence this process. One report implies that certain endogenous ROS concentrations are 
essential in differentiating myoblasts and that the addition of antioxidants to the cells resulted 
in differentiation inhibition. In contrast, Cyclosporin A-induced ROS generation has been 
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shown to block myoblast differentiation in early myoblasts. The conclusion was that the 
addition of Cyclosporin A to differentiating cells led to toxic levels of ROS, blocking muscle 
differentiation even when antioxidants were added (206). Another report from the same 
group shows that the ROS-induced activation of NF-κB/iNOS pathway is necessary for 
differentiation (207). Other studies provide evidence for a negative effect of ROS on 
myoblast differentiation. Langen et al. described that oxidative stress per se is sufficient to 
block myogenic late differentiation (208). H2O2 administered in different concentration (20-
200 µM) reduced myogenin and MHC protein content, creatine kinase activity as well as 
troponin I gene transcription all in a dose-dependent manner and that the inhibition of 
myotube formation was reversible when NAc was added to the culture medium (208). 
Furthermore, it was demonstrated that 25 µM H2O2 markedly reduced Myf5 and MRF4 gene 
expression 2-3 fold, whereas myogenin was even 60-fold down-regulated (209). Applying 1 
mM H2O2 to C2C12 cells decreases Myf5 and MHC gene expression (210). These data 
clearly support the idea that expression of differentiation progression markers, such as 
myogenin and MHC are very susceptible to oxidative stress, and are thus La-sensitive. As 
the literature reports contrasting outcomes of ROS-exposure to myoblasts, the notion that 
ROS can have different outcomes depending on the dose (140, 145). Regarding the results 
in this thesis it can be implied that La highly elevates ROS levels that result in inhibition of 
late differentiation. 
Regarding the data attained in this study and the information available from the literature for 
late differentiation markers as well as the findings on the reversibility of the La-effect by the 
addition of antioxidants, it can be conclusively argued that the La-induced effects are 
mediated via the formation of ROS. However, it would be interesting to see why cells show 
delayed differentiation and not total inhibition. There is abundant evidence that muscle is 
capable of antioxidative adaptation in response to exercise (reviewed in (211, 212)). For 
example, SOD has been shown to be increased following exercise in an intensity-dependent 
manner (213–215). Similar findings were published regarding GPx and Cat (216). Possibly 
after a few La exposures, cells adapt by increasing their antioxidative capacity, i.e. 
expression of SOD, GPx, and/or Cat and hence at a later stage La-induced ROS-signalling is 
inhibited and differentiation can progress.  
 
The third aim of this study was to elucidate whether La levels influence the skeletal muscle 
adaptation signalling molecule p38 MAPK and its downstream targets H3K4me3 and 
H3K27me3 to further establish the important role of La as a metabolic signal of gene 
expression. The results presented here show a clear inhibition of p38 MAPK phosphorylation 
by 20 mM La DM compared to control treatment, i.e. 0 mM La DM. Serum-deprivation 
without the addition of La led to increased p38 MAPK activation within one hour of treatment, 
Discussion 
 
59 
 
whereas La-treated samples failed to increase phosphorylation levels above baseline over 
the whole time course of the experiment. Further prove for the involvement of p38 MAPK in 
mediating the La effect is drawn from experiments including the p38 MAPK specific inhibitor 
SB203580. Clearly, cells treated with 20 mM La DM elicited the same phenotype as the cells 
treated with 0 mM La DM + SB 203580, i.e. high content of early differentiation markers and 
low content of late differentiation markers compared to 0 mM La DM-treated samples. 
Up to the present time, no report has been published to specifically investigate the activation 
of p38 MAPK in response to La in myoblasts. Nevertheless, one study found elevated p38 
MAPK activation in response to incubation with 20 mM La medium, simulating ischemia in 
adult rat ventricular myocytes (217). However, ischemic incubation media also contained 
sodium dithionite, a strong reducing agent that might account for the observed differences in 
p38 phosphorylation given its redox sensitive activity further explained below. Their finding is 
nevertheless in line with another study that found increased phosphorylated p38 MAPK, JNK, 
and ERK levels in stem/progenitor cells grown in vivo in matrigel plugs in mice (218). Here, 
experimental setup and analysed cell type differ immensely and care has to be taken when 
comparing results from this study with the ones reported here. In contrast, Mendler et al. 
demonstrated that La inhibits p38 MAPK and JNK activation in cytotoxic t-cells (CTLs) 
leading to CTL inhibition by tumour lactic acidosis (158). Obviously, La-induced regulation of 
p38 MAPK depends on many diverse factors, such as cell type or environment that remain 
largely unknown. p38 MAPK was shown to be activated via the apoptosis-stimulating kinase 
1 (ASK1) following elevated ROS formation (146, 219, 220). Another study has shown that 
especially mitochondrial ROS initiate p38 MAPK activation (221). Although the literature 
agrees that ROS activates p38 MAPK the underlying mechanisms remain less clear (140). 
Nevertheless, the here presented findings are in contrast to the literature which would predict 
increased activation of p38 MAPK mediated via ROS formation. Only little is known about the 
mechanisms of p38 MAPK activation by ROS, so it can only be speculated about reasons to 
explain this phenomenon. p38 MAPK activation requires either phosphorylation by an 
upstream kinase such as ASK1 and/or inhibition of the dephosphorylation by a MAPK 
phosphatase (MKP). MKPs are negative regulators of MAPKs as their phosphatase activity 
leads to inactivation of these (222–225). Possibly, one or both of these events were inhibited 
by the La molecule. For example, exposure to low light associated with lower levels of ROS 
production elicited lower expression of MKP1 in retinal pigment endothelial cells whereas 
high light doses decreased its expression and led to increased MAPK activation (226). This 
implies that the activation of MAPK by ROS depends on their concentration which is in line 
with findings explained above of ROS effects on skeletal muscle differentiation (140, 145). 
Another underlying mechanism could be increased Cdkn1a expression. ROS-induced ASK1 
activation and subsequent p38 MAPK phosphorylation have been shown to induce apoptosis 
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in several cancer cell lines. Overexpression of p21 led to its increased binding to ASK1, 
subsequent ASK1 inactivation and hence, prevention of apoptosis (227). Although this 
mechanism has not been demonstrated in skeletal muscle cells, possibly increased p21 
levels observed following La treatment could prevent the activation of p38 MAPK by ASK1 
inhibition. However, expression of Cdkn1a was measured 6 h, p38 MAPK activation was 
decreased as soon as 15 min after start of the La treatment. So, to prove this concept gene 
expression and protein levels of p21 have to be closer investigated. However, as overall 
knowledge about detailed mechanisms on p38 MAPK activation is scarce more research is 
necessary to address the question which mechanisms are influenced by La to inhibit its 
phosphorylation. 
Collectively the data provide evidence that the delay in late differentiation induced by La 
treatment is at least partly due to decreased activation of the pro-myogenic p38 MAPK. 
However, the data is not conclusive on how p38 MAPK is inactivated, as the La-induced 
increase in ROS should predictably have led to increased activation. Moreover, p38 MAPK 
was shown to induce cell cycle arrest (102), but here, p38 MAPK is not activated by La but 
proliferation ceases. Further investigations need to shed light on which p38 MAPK-
independent pathways are activated to increase Cdkn1a gene expression. 
p38 MAPK has several downstream targets exerting its differentiation driving effect on. Two 
key targets are the histone modifications H3K4me3 and H3K27me3 (72, 73, 80) which both 
lead to differentiation progression during myogenesis. Notably, the H3K4me3 pattern 
strongly resembles that of p38 MAPK activation, and H3K27me3 also increases within the 
same time frame indicating a direct connection between the two events. Both results confirm 
the known mechanisms and furthermore support the notion that differentiation delay caused 
by La is caused by diminished p38 MAPK activation. This observation might also explain the 
finding that acutely Myf5 gene expression is reduced, as this was also shown to be a p38 
MAPK-dependent process (77). However, it does not account for the increased abundance 
after 5 days of incubation for which the reasons remain unknown with the given data.  
When C2C12 cells were intermittently incubated with 20 mM La DM during an experiment 
lasting 5 days (a simulated microcycle of resistance or high intensity endurance training), 
H3K4me3 was significantly down-regulated in La-treated myoblasts compared to control 
samples which is in line with the data from the acute experiments. Interestingly, after data 
analysis distinguishing myoblasts from myotubes, it was observed that in myotubes no signal 
could be detected for H3K4me3 in 20 mM La DM-treated samples. This finding indicated that 
H3K4me3 is massively downregulated, but not necessarily totally abolished. The absence of 
signal might be explicable by the methodology used. In fluorescent quantification a threshold 
for a signal has to be set and if this is above a weak signal the measurement will give 0. 
Nonetheless, a profound reduction of H3K4me3 has to be reported. Further analysis is 
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however necessary to put this finding in context. To conclusively prove the concept of p38 
MAPK inactivation and associated diminished inhibition of differentiation events, rescue 
experiments by transfection of cells with a p38 MAPK activator, and chromatin 
immunoprecipitation analysis to investigate genes affected by reduced H3K4me3 and 
H3K27me3 would be essential. Additionally, SB203580 experiments should be conducted 
testing the p38 MAPK-dependency of H3K4me3 and H3K27me3. 
 
The fourth aim of the study was to confirm that the aforementioned mechanisms observed in 
differentiating skeletal muscle stem cells are conserved during differentiation and remain 
active in differentiated muscle tissue exposed to similar La concentrations evoked by 
exercise in vivo. 
High intensity resistance training was chosen as a model of increased metabolic stress 
accompanied by high intramuscular La levels (228–231). Several considerations led to the 
fact that La levels were not determined in this study: [1] A method to determine intramuscular 
La levels during and/or after exercise was not available. [2] The exercise stimulus was only 
applied in one leg and exercise time was short. Measuring systemic La levels would have 
possibly led to distorted results. Systemic La levels depend on several factors, such as La 
production, muscular La export into the bloodstream, and uptake by different organs that use 
La as an energy substrate, e.g. heart, liver, brain, passive musculature. All these factors vary 
widely between subjects and are therefore unlikely to reflect local La production. This notion 
is supported by Buitrago et al. who could not detect any increases in systemic La levels 
following a HIT protocol although the intensity of work was found to be higher by 
measurement of oxygen used. The group explained their finding by the shortened exercise 
time of HIT protocols not allowing enough time for La to accumulate in the blood (232). In this 
study presented her exercise time varied immensely (HIT: 1 set of 20 repetitions; STD: 3 sets 
with 10 repetitions with a 3 min break in between) further justifying this approach. [3] The 
tight time frame of muscle biopsies placed discomfort on the subjects and taking blood for La 
measurement would have further distressed them. As results obtained for the above 
mentioned reasons might not be reliable, it was decided against additionally measuring 
systemic La levels. The HIT and STD protocols nevertheless differed massively in their 
design and information from the literature listed above suggests considerably higher 
metabolic stress, amongst other by higher La levels, during the HIT protocol. 
Up to the present time, no study has investigated the effects of a certain training stimulus on 
trimethylation of H3K4 or H3K27. In general, knowledge regarding histone modifications 
following exercise is humble. The present study was designed to address this topic and 
additionally added a tight time frame to be furthermore able to assess temporal relationships 
between key regulators, such as p38 MAPK, and histone modifications, such as H3K4me3 
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and H3K27me3. Comparison of a HIT to a STD stimulus revealed that HIT leads to a 
pronounced decrease in p38 MAPK phosphorylation in human muscle immediately after 
exercise that only starts recovering 4 h post-exercise. The results further showed a 
pronounced loss of H3K4me3 as soon as 15 min following HIT, with a significant reduction in 
H3K4me3 still being present after 4 h post-exercise. H3K27me3 was positively affected for 
by HIT, both modifications indicating an expression-repressive epigenetic landscape 
following HIT. Only a few studies have been published that describe the changes on histone 
modifications associated with promoter regions of specific genes in order to gain a better 
understanding of how exercise may differentially affect transcription in muscle in response to 
different modes of exercise (reviewed in (233)). A single bout of endurance exercise (cycling 
for 60 min at 76% VO2peak) led to a global increase in H3K36 acetylation, a modification 
that is associated with transcriptional elongation. Furthermore, the same study showed that 
AMPK and CaMKII activation led to nuclear export of histone deacetylases 4 and 5 (HDAC4 
and 5) rendering these enzymes to suppress histone acetylation (115). Additionally, 
epigenetic modifications have been shown to depend on metabolic signals, such as AMPK 
and CaMK II (10). This delivers a possible explanation for the finding of a study where a 
reduction of DNA methylation of the promoters for e.g. PGC1α, and subsequent increased 
gene expression was found to be exercise intensity dose-dependent (11). Taking all this 
evidence into account, it appears that a metabolic stimulus such as La is able to induce 
epigenetic modifications that alter gene expression and hence, skeletal muscle adaptation. 
Although other stimuli arising with exercise and physical activity, e.g. mechanical stress, 
might also affect epigenetic modifications occurring with resistance exercise, together with 
the in vitro data, it can be assumed that the HIT effect exerted on histone modifications is 
primarily of metabolic nature. The HIT stimulus applied in this study was very high and 
evoked histone modifications related to inhibition of gene expression. With regards to studies 
finding a positive correlation of exercise intensity and gene expression induction, findings 
from the study presented here imply that very high exercise intensities might regulate gene 
expression negatively. Further research is nevertheless necessary, e.g. gene expression 
analysis, chromatin immunoprecipitation to determine genes labelled with the H3K4me3 and 
H3K27me3 mark, and further training intervention studies in vivo to elucidate the functional 
relevance of the here described modification and additionally involved mechanisms. 
Conclusively, these data are first evidence to show that in differentiating myoblasts La 
reduces p38 MAPK activation and subsequent H3K4me3 and H3K27me3. Furthermore, it 
was possible to demonstrate for the first time that this mechanism is conserved in 
differentiated muscle tissue and also applies in vivo. Taken together, it is concluded that 
epigenetic modifications are inducible by La as a metabolic signal and that epigenetic 
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responses to exercise and physical activity are exercise-intensity and hence, metabolic 
environment dependent. 
 
Exercise and physical activity adaptations with the desired outcome being improved function 
and/or increased muscle mass requires the preservation of nuclear domains, and therefore 
the activation, proliferation, differentiation and fusion of SCs with skeletal muscle fibres. The 
data obtained from in vitro experiments imply that common views on design and 
periodisation of training (as well as the prescription of antioxidant nutritional supplements) 
should be reassessed. La modifies skeletal muscle adaptation by delaying late differentiation 
of activated SCs via a ROS-sensitive signalling pathway. Suggestively, if this mechanism 
also exists in vivo, it might lead to diminished or delayed fusion of SCs with existing skeletal 
muscle fibres and hence, impaired skeletal muscle adaptation. So in order to design an 
optimal training regime with the best possible adaptational response, the following proposed 
training regimen considers these results. 
Suggestively, one should start with a type of training to increase the SC pool most efficiently. 
Several human studies reported an increase in SC number of over 80% 5-8 days after a 
single bout of maximal eccentric contraction (234–236). In contrast, other studies applying an 
endurance type training (38, 39) or lower intensity resistance training (39, 237–239) in 
humans could only demonstrate markedly smaller changes in SC pool expansion of 30-
62.5%. The next cycle within the training regimen should lead to the withdrawal from the cell 
cycle and promotion of early differentiation. Considering the in vitro data reported here, a 
high intensity endurance training cycle accompanied by high La levels should be an efficient 
way to drive proliferating SCs to withdraw from the cell cycle and into the early differentiation 
phase. Although several molecular promoters (240) and involved signalling pathways 
(reviewed in (241)) of myoblast fusion into myotunbes or with existing myofibres were 
identified, no data is available on how different types of exercise modify this process. 
However, it should not be accompanied by high La levels as our data implies that these 
prevent further differentiation and fusion of myoblasts with already existing myofibres, 
possibly eventually suppressing hypertrophy. Nevertheless, further research is necessary to 
elucidate which sequential pattern and timing of training stimuli elicits the most effective 
training programme. 
The in vivo study was predominantly conducted to establish whether the mechanism of 
decreased p38 MAPK activation and subsequent histone modifications caused by high La 
levels is conserved during differentiation. Unfortunately, no measurements were included to 
elucidate the meaning of the intracellular signalling modifications and its functional 
consequences regarding skeletal muscle adaptation. Hence, from these data no practical 
application can be derived. However, the conservation of the signalling pathways during 
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differentiation implies that differentiated myoblasts might be a suitable model for the study of 
histone modifications (at least for H3K4 and H3K27) exerted by different training stimuli, such 
as metabolic stress or mechanical strain. 
The finding that the La effects are at least partly mediated by ROS furthermore suggests that 
the use of antioxidants as nutritional supplements could influence the process of skeletal 
muscle adaptation. The use of antioxidants is common among athletes with the intention to 
avoid deleterious effects of oxidative stress arising with exercise (242). Recently, more and 
more studies imply that antioxidative substances attenuate beneficial effects of exercise and 
physical activity due to the inhibition of essential ROS-signalling and subsequent cellular 
adaptation (144, 243–246). For La-induced adaptations as in high intensity endurance 
training the use of antioxidants might be deleterious at first as it might prevent cell cycle 
withdrawal and induction of early differentiation. However, at some point it could be beneficial 
as it possibly accelerates the delayed differentiation process induced by the metabolic signal. 
Obviously, the form of exercise also elicits implications on nutritional supplementation 
recommendations and even the timing of their application has to be considered. However, 
advising on nutritional supplements needs precaution due to its complicated nature and is 
not further discussed here. 
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5 ConclusionCONCLUSION 
 
The results presented here provide strong evidence that La is indeed a metabolic signal for 
skeletal muscle adaptation in vitro (Figure 5.1). In differentiating myoblasts it induces the 
formation of ROS which downstream lead to several signalling events. Firstly, it leads to the 
withdrawal from the cell cycle by up-regulation of Cdkn1a, the gene encoding the cell cycle 
control protein p21 which induces cell cycle arrest. Markers of the early differentiation phase 
(Pax7 and Myf5) are also induced. However, late differentiation is timely delayed in a dose-
dependent manner. This effect is possibly mediated via the inhibition of p38 MAPK and 
subsequent diminished H3K4me3 and H3K27me3. Conduction of a human intervention study 
revealed that p38 MAPK is also regulated by metabolic signals in vivo and that the 
mechanism of inactivation of p38 MAPK and down-regulation of H3K4me3 and H3K27me3 is 
conserved during differentiation and still present in differentiated skeletal muscle tissue. 
Furthermore, the findings propose that traditional views on training design should be 
reassessed and possibly nutritional supplementation be reconsidered. Additionally, 
differentiated C2C12 myoblasts might propose a usable model to study epigenetic 
modifications as at least histone modifications are conserved in differentiated tissue in vivo. 
 
 
Figure 5.1: La induces cell cycle arrest and inhibits differentiation progression. Incubation with La enhances the 
serum deprivation-induced withdrawal from the cell cycle. This is possibly mediated by the ROS-induced 
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expression of Cdkn1a, the gene encoding the cell cycle regulator p21 which leads to cell cycle arrest. ROS were 
shown to activate ASK1, MKK3/6, and p38. Although La induces the production of ROS, p38 MAPK and 
subsequent H3K4me3 and H3K27me3 are inactivated resulting in late differentiation delay. Suggestively, La 
regulates a signalling event downstream of ROS that prevents p38 MAPK activation and subsequently H3K4me3 
and H3K27me3 and associated differentiation progression. La – lactate; ROS – reactive oxygen species; Cdkn1a 
– cyclin-dependent kinase inhibitor 1a; p38 – p38 mitogen-activated protein kinase; MKK3/6 – MAPK kinase 3/6; 
ASK1 – apoptosis-stimulating kinase 1; H3Kxme3 – trimethylated histone 3 at lysine x. 
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7 AppendixAPPENDIX 
 
Table A.1: La delayed myogenin synthesis in C2C12 cells 
A           
Myogenin [%] D1 D2 D3 D4 D5 
0 mM La DM 0.06 ± 0.04 2.78 ± 0.39 5.79 ± 1.14 10.01 ± 1.05 7.87 ± 1.45 
10 mM La DM 0.0 1.66 ± 0.30 6.47 ± 0.67 6.92 ± 0.72 9.85 ± 1.69 
20 mM La DM 0.0 1.09 ± 0.21 2.65 ± 0.31 4.14 ± 0.66 5.07 ± 0.63 
B 
p-values D1 D2 D3 D4 D5 
0 vs. 10 mM - - - - - 
0 vs. 20 mM - 0.011 < 0.001 0.018 - 
10 vs. 20 mM - - 0.001 - - 
 
 
Table A.2: La delayed MHC synthesis in C2C12 cells in a dose-dependent manner 
A 
MHC [%] D1 D2 D3 D4 D5 
0 mM La DM 0.0 0.47 ± 0.22 2.89 ± 0.47 10.03 ± 1.26 31.51 ± 1.75 
10 mM La DM 0.0 0.13 ± 0.08 1.49 ± 0.22 12.56 ± 1.14 29.48 ± 1.49 
20 mM La DM 0.0 0.0 0.02 ± 0.02 0.93 ± 0.26 6.08 ± 0.70 
B 
p-values D1 D2 D3 D4 D5 
0 vs. 10 mM - 0.011 <0.001 - - 
0 vs. 20 mM - < 0.001 < 0.001 < 0.001 0.027 
10 vs. 20 mM - < 0.001 0.001 - - 
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Table A.3: La altered gene expression of cell cycle control genes Cdkn1a and Trp53 
A 
x-fold increase Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
Trp53 1 0.61 ± 0.03 0.55 ± 0.05 0.79 ± 0.06 0.56 ± 0.02 1.98 ± 0.03 
Cdkn1a 1 1.24 ± 0.32 2.67 ± 0.30 1.56 ± 0.04 2.03 ± 0.15 1.98 ± 0.18 
B             
Trp53 p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
Pre   - 0.017 - - - 
0 mM -   0.038 - - - 
20 mM 0.017 0.038   - - - 
20mM + AA - - -   - - 
20 mM + NAc - - - -   - 
20 mM + LA - - - - -   
C             
Cdkn1a p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
Pre   0.001 p < 0.001 0.022 p < 0.001 0.002 
0 mM 0.001   - 0.008 - - 
20 mM p < 0.001 -   0.008 - - 
20mM + AA 0.022 0.008 0.008   0.011 - 
20 mM + NAc p < 0.001 - - 0.011   - 
20 mM + LA 0.002 - - - -   
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Table A.4: La influenced gene expression of Pax7, Myf5, myogenin, MHC 1, and MHC2 
A 
x-fold increase Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pax7 1 0.88 ± 0.02 0.42 ± 0.03 1.45 ± 0.18 1.22 ± 0.08 1.06 ± 0.08 
Myf5 1 0.97 ± 0.02 0.72  ± 0.01 1.15 ± 0.03 1.11 ± 0.02 1.17 ± 0.19 
Myogenin 1 2.64 ± 0.18 1.40 ± 0.12 3.31 ± 0.45 2.65 ± 0.45 3.15 ± 0.11 
MHC1 1 2.33 ± 0.01 1.40 ± 0.16 1.87 ± 0.49 2.45 ± 0.30 2.59 ± 0.15 
MHC2 1 2.40 ± 0.65 1.22 ± 0.48 3.6 ± 0.27 1.75 ± 0.13 1.86 ± 0.49 
B             
Pax7 p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pre   - 0.01 0.03 - - 
0 mM -   0.033 0.009 - - 
20 mM 0.01 0.033   p < 0.001 0.002 0.006 
20mM + AA 0.03 0.009 p < 0.001   - 0.067 
20 mM + NAc - - 0.002 -   - 
20 mM + LA - - 0.006 0.067 -   
C             
Myf5 p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pre   - - - - - 
0 mM -   - - - - 
20 mM - -   0.027 0.046 0.022 
20mM + AA - - 0.027   - - 
20 mM + NAc - - 0.046 -   - 
20 mM + LA - - 0.022 - -   
D             
Myogenin p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pre   0.016 - 0.003 0.016 0.004 
0 mM 0.016   - - - - 
20 mM - 0.066   0.007 0.064 0.012 
20mM + AA 0.003 - 0.007   - - 
20 mM + NAc 0.016 - 0.064 -   - 
20 mM + LA 0.004 - 0.012 - -   
E             
MHC1 p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pre   0.027 - - 0.018 0.011 
0 mM 0.027   - - - - 
20 mM - -   - 0.089 0.049 
20mM + AA - - -   - - 
20 mM + NAc 0.018 - 0.089 -   - 
20 mM + LA 0.011 - 0.049 - -   
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F             
MHC2 p-values Pre 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA
Pre   - - 0.01 - - 
0 mM -   - - - - 
20 mM - -   0.015 - - 
20mM + AA 0.01 - 0.015   0.053 0.071 
20 mM + NAc - - - 0.053   - 
20 mM + LA - - - 0.071 -   
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Table A.5: La-induced delayed differentiation in C2C12 cells was reversible by the use of antioxidants 
A           
[%] positive cells 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
Pax7 3.6 ± 0.8 10.3 ± 1.2 4.7 ± 0.9 6.1 ± 1.2 8.6 ± 1.9 
Myf5 1.7 ± 0.5 3.6 ± 0.9 0.9 ± 0.2 2.1 ± 0.4 1.6 ± 1.5 
Myogenin 30.3 ± 2.4 17.2 ± 1.2 34.1 ± 1.3 32.1 ± 1.5 34.9 ± 1.4 
MHC 28.7 ± 2.0 15.4 ± 1.8 30.5 ± 1.7 30.3 ± 1.4 29.4 ± 1.6 
B           
Pax7 - p-values 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
0 mM   0.007 - - - 
20 mM 0.007   0.049 - - 
20mM + AA - 0.049   - - 
20 mM + NAc - - -   - 
20 mM + LA - - - -   
C           
Myf5 - p-values 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
0 mM   - - - - 
20 mM -   0.009 - - 
20mM + AA - 0.009   - - 
20 mM + NAc - - -   - 
20 mM + LA - - - -   
D           
Myogenin - p-values 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
0 mM   <0.001 - - - 
20 mM < 0.001   <0.001 <0.001 <0.001 
20mM + AA - <0.001   - - 
20 mM + NAc - <0.001 -   - 
20 mM + LA - <0.001 - -   
E           
MHC - p-values 0 mM 20 mM 20mM + AA 20 mM + NAc 20 mM + LA 
0 mM   <0.001 - - - 
20 mM <0.001   <0.001 <0.001 <0.001 
20mM + AA - <0.001   - - 
20 mM + NAc - <0.001 -   - 
20 mM + LA - <0.001 - -   
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Table 5: La-induced delayed differentiation in C2C12 cells is comparable to p38 MAPK-inhibition 
A         
[%] positive cells 0 mM 0 mM + DMSO 0 mM + SB203580 20 mM  
Pax7 3.84 ± 0.81 4.69 ± 0.86 11.35 ± 1.20 9.57 ± 0.89 
Myf5 0.77 ± 0.23 0.79 ± 0.21 3.74 ± 0.43 5.89 ± 2.21 
Myogenin 29.79 ± 0.82 32.48 ± 0.60 17.96 ± 1.48 18.62 ± 1.91 
MHC 35.43 ± 2.55 32.20 ± 1.73 22.58 ± 0.95 19.22 ± 2.00 
B 
Pax7 - p-values 0 mM 0 mM + DMSO 0 mM + SB203580 20 mM  
0 mM   - p < 0.001 0.001 
0 mM + DMSO -   p < 0.001 0.005 
0 mM + SB203580 p < 0.001 p < 0.001   - 
20 mM  0.001 0.005 -   
C 
Myf5 - p-values 0 mM 0 mM + DMSO 0 mM + SB203580 20 mM  
0 mM   - p < 0.001 0.046 
0 mM + DMSO -   p < 0.001 0.047 
0 mM + SB203580 p < 0.001 p < 0.001   - 
20 mM  0.046 0.047 -   
D 
Myogenin - p-values 0 mM 0 mM + DMSO 0 mM + SB203580 20 mM  
0 mM   - 0.019 0.035 
0 mM + DMSO -   p < 0.001 p < 0.001 
0 mM + SB203580 0.019 p < 0.001   - 
20 mM  0.035 p < 0.001 -   
E 
MHC - p-values 0 mM 0 mM + DMSO 0 mM + SB203580 20 mM  
0 mM   - p < 0.001 p < 0.001 
0 mM + DMSO -   0.006 p < 0.001 
0 mM + SB203580 p < 0.001 0.006   - 
20 mM  p < 0.001 p < 0.001 -   
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